Indian Patents
Title of Invention

BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS
Abstract The present invention relates to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the R1, Z, Y, RA, and W groups of formula I are as defined herein. The invention also provides pharmaceutically acceptable compositions and methods of suing the compositions in the treatment of various disorders.
Full Text PCT/US2004/036297
WO2005/042497
BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS
TECHNICAL FIELD OF THE INVENTION
[0001] The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
BACKGROUND OF THE INVENTION
[0002] Na channels are central to the generation of action potentials in all excitable cells such as neurons and myocytes. They play key roles in excitable tissue including brain, smooth muscles of the gastrointestinal tract, skeletal muscle,.the peripheral, nervous system, spinal cord and. airway. As such they play key roles in a variety of disease states such as epilepsy (See, Moulard, B. and D. Bertrand (2002) "Epilepsy and sodium channel blockers" Expert Opin. Ther. Patents 12(1): 85-91)), pain (See, Waxman, S. G., S. Dib-Hajj, et al. (1999) "Sodium channels and pain" Proc Natl Acad Sci U S A 96(14): 7635-9 and Waxman, S. G., T. R. Cummins, et al. (2000) "Voltage-gated sodium channels and the molecular pathogenesis of pain: a review" J Rehabil Res Dev 37(5): 517-28), myotonia (See. Meola, G. and V. Sansone (2000) 'Therapy in myotonic disorders and in muscle channelopathies" Neurol Sci 21(5): S953-61 and Mankodi, A. and C. A. Thornton (2002) "Myotonic syndromes" Curr Opin Neurol 15(5): 545-52), ataxia (See, Meisler, M. H., J. A. Kearney, et al. (2002) "Mutations of voltage-gated sodium channels in movement disorders and epilepsy" Novartis Found Symp 241: 72-81), multiple sclerosis (See, Black, J. A.,
-1-

WO 2005/042497 PCT/US2004/036297
S. Dib-Hajj, et al. (2000) "Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis" Proc Natl Acad Sci U S A 97(21): 11598-602, and Renganathan, M., M. Gelderblom, et al. (2003) "Expression of Na(v)1.8 sodium channels perturbs the firing patterns of cerebellar purkinje cells" Brain Res 959(2): 235-42), irritable bowel (See, Su, X., R. E. Wachtel, et al. (1999) "Capsaicin sensitivity and voltage-gated sodium currents in colon sensory neurons from rat dorsal root ganglia" Am J Phvsiol 277(6 Pt 1): G1180-8, and Laird, J. M., V. Souslova, et al. (2002) "Deficits in visceral pain and referred hyperalgesia in Navl.8 (SNS/PN3)- null mice" J Neurosci 22(19): 8352-6), urinary incontinence and visceral pain (See,Yoshimura, N., S. Seki, et al. (2001) "The involvement of the tetrodotoxin-resistant sodium channel Na(v)1.8 (PN3/SNS) in a rat model of visceral pain" J Neurosci 21(21): 8690-6), as well as an array of psychiatry dysfunctions such as anxiety and depression (See, Hurley, S. C. (2002) "Lamotrigine update and its use in mood disorders" Ann Pharmacother 36(5): 860-73).
-2-
[0003] Voltage gated Na channels comprise a gene family consisting of 9 different subtypes (NaVl.l-NaV1.9). As shown in Table 1, these subtypes show tissue specific localization and functional differences (See, Goldin, A. L. (2001) "Resurgence of sodium channel research" Annu Rev Physiol 63: 871-94). Three members of the gene family (NaV1.8, 1.9, 1.5) are resistant to block by the well-known Na channel blocker TTX, demonstrating subtype specificity within this gene family. Mutational analysis has identified glutamate 387 as a critical residue for TTX binding (See. Noda, M., H. Suzuki et al. (1989) "A single point mutation confers tetrodotoxin and saxitoxin insensitivity on the sodium channel II" FEBS Lett 259(1): 213-6). [0004] Table 1 (Abbreviations: CNS = central nervous system, PNS = peripheral nervous sytem, DRG = dorsal root ganglion, TG = Trigeminal ganglion):



WO 2005/042497 PCT/US2004/036297
[0005] In general, voltage-gated sodium channels (NaVs) are responsible for initiating the rapid upstroke of action potentials in excitable tissue in nervous system, which transmit the electrical signals that compose and encode normal and aberrant pain sensations. Antagonists of NaV channels can attenuate these pain signals and are useful for treating a variety of pain conditions, including but not limited to acute, chronic, inflammatory, and neuropathic pain. Known NaV antagonists, such as TTX, lidocaine (See, Mao, J. and L. L. Chen (2000) "Systemic lidocaine for neuropathic pain relief Pain 87(1): 7-17.) bupivacaine, phenytoin (See, Jensen, T. S. (2002) "Anticonyulsants in neuropathic pain: rationale and clinical evidence" Eur J Pain 6 (Suppl A): . 61-8), lamotrigine (See, Rozen, T. D. (2001) "Antiepileptic drugs in the imanagement of cluster headache and trigemmal neuralgia" Headache 41 Suppl 1: S25-32 and Jensen, T. S. (2002) "Anticonvulsants in neuropathic pain: rationale and clinical evidence" Eur J Pain 6 (Suppl A): 61-8.), and carbamazepine (See, Backonja, M. M. (2002) "Use of anticonvulsants for treatment of neuropathic pain" Neurology 59(5 Suppl 2): S14-7), have been shown to be useful attenuating pain in humans and animal models.
[0006] Hyperalgesia (extreme sensitivity to something painful) that develops in the presence of tissue injury or inflammation reflects, at least in part, an increase in the excitability of high-threshold primary afferent neurons innervating the site of injury. Voltage sensitive sodium channels activation is critical for the generation and propagation of neuronal action potentials. There is a growing body of evidence indicating that modulation of NaV currents is an
- 3 ¦

WO 2005/042497 PCT/US2004/036297
endogenous mechanism used to control neuronal excitability (See, Goldin, A. L. (2001) "Resurgence of sodium channel research" Atinu Rev Physiol 63: 871-94.). Several kinetically and pharmacologically distinct voltage-gated sodium channels are found in dorsal root ganglion (DRG) neurons. The TTX-resistant current is insensitive to micromolar concentrations of tetrodotoxin, and displays slow activation and inactivation kinetics and a more depolarized activation threshold when compared to other voltage-gated sodium channels. TTX-resistant sodium currents are primarily restricted to a subpopulation of sensory neurons likely to be involved in nociception. Specifically, TTX-resistant sodium currents are expressed almost exclusively in neurons that have a small cell-body diameter; and give rise to small-diameter slow-conducting axons and that are responsive to capsaicin. A large body of experimental evidence demonstrates that TTX-resistant sodium channels are expressed on C-fibers and are important in the transmission of nociceptive information to the spinal cord. [0007] Intrathecal administration of antisense oligo-deoxynucleotides targeting a unique region of the TTX-resistant sodium channel (NaV1.8) resulted in a significant reduction in PGE2-induced hyperalgesia (See, Khasar, S. G., M. S. Gold, et al. (1998) "A tetrodotoxin-resistant sodium current mediates inflammatory pain in the rat" Neurosci Lett 256(1): 17-20). More recently, a knockout mouse line was generated by Wood and colleagues, which lacks functional NaV1.8. The mutation has an analgesic effect in tests assessing the animal's response to the inflammatory agent carrageenan (See, Akopian, A. N., V. Souslova, et al. (1999) "The .tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways" Nat . Neurosci 2(6): 541-8.). In addition, deficit in both mechano- and thermoreception were observed in these animals. The analgesia shown by the Navl.8 knockout mutants is consistent with observations about the role of TTX-resistant currents in nociception.
[0008] Immunohistochemical, in-situ hybridization and in-vitro electrophysiology experiments have all shown that the sodium channel NaV1.8 is selectively localized to the small sensory ¦neurons of the dorsal root ganglion and trigeminal ganglion (See, Akopian,. A. N., L. Sivilotti, et al. (1996) "A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons" Nature 379(6562): 257-62.). The primary role of these neurons is the detection and transmission of nociceptive stimuli. Antisense and immunohistochemical evidence also supports a role for NaV1.8 in neuropathic pain (See, Lai, J., M. S. Gold, et al. (2002) "Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8" Pain 95(1-
-4-

WO2005/042497 PCT/US2004/036297
2): 143-52, and Lai, J., J. C. Hunter, et al. (2000) "Blockade of neuropathic pain by antisense
targeting of tetrodotoxin- resistant sodium channels in sensory neurons" Methods Enzymol 314:
201-13.) NaV1.8 protein is upregulated along uninjured C-fibers adjacent to the nerve injury.
Antisense treatment prevents the redistribution of NaV1.8 along the nerve and reverses
neuropathic pain. Taken together the gene-knockout and antisense data support a role for
NaV1.8 in the detection and transmission of inflammatory and neuropathic pain.
[0009] In neuropathic pain states there is a remodeling of Na channel distribution and subtype.
In the injured nerve, expression of NaV1.8 and NaV1.9 are greatly reduced whereas expression
of the TTX sensitive subunit NaV1.3 is 5-10 fold upregulated (See, Dib-Hajj, S. D., J. Fjell, et al.
(1999) "Plasticity of sodium channel expression in DRG neurons in the chronic constriction
injury model of neuropathic pain." Pain 83(3): 591-600.) The timecourse of the increase in
NaV1.3 parallels the appearance of allodynia in animal models subsequent to nerve injury. The
biophysics of the NaV1.3 channel is distinctive in that it shows very fast repriming after
inactivation following an action potential. This allows for sustained rates of high firing as is
often seen in the injured nerve (See, Cummins, T. R., F. Aglieco, et al. (2001) "Navl.3 sodium
channels: rapid repriming and slow closed-state inactivation display quantitative differences after
expression in a mammalian cell line and in spinal sensory neurons" J Neurosci 21(16): 5952-
61.) NaV1.3 is expressed in the central and peripheral systems of man. NaV1.9 is similar to
NaV1.8 as it is selectively localized to small sensory neurons of the dorsal root ganglion and
. trigeminal ganglion (See. Fang, X., L. Djouhri, et al. (2002). "The presence and role of the
tetrodotoxin-resistant sodium channel Na(v)1.9 (NaN) in nociceptive primary afferent neurons." .
J Neurosci 22(17): 7425-33.). It has a slow rate of inactivation and left-shifted voltage
dependence for activation (See, Dib-Hajj, S., J. A. Black, et al. (2002) "NaN/Navl.9: a sodium
channel with unique properties" Trends Neurosci 25(5): 253-9.). These two biophysical
properties allow NaV1.9 to play a role in establishing the resting membrane potential of
nociceptive neurons. The resting membrane potential of NaV1.9 expressing cells is in the -55 to
-50mV range compared to -65mV for most other peripheral and central neurons. This persistent
depolarization is in large part due to the sustained low-level activation of NaV1.9 channels.
This depolarization allows the neurons to more easily reach the threshold for firing action
potentials in response to nociceptive stimuli. Compounds that block the NaV1.9 channel may
play an important role in establishing the set point for detection of painful stimuli. In chronic
-5-

WO2005/042497 PCT/US2004/036297
pain states, nerve and nerve ending can become swollen and hypersensitive exhibiting high frequency action potential firing with mild or even no stimulation. These pathologic nerve swellings are termed neuromas and the primary Na channels expressed in them are NaV1.8 and NaV1.7 (See, Kretschmer, T., L. T. Happel, et al. (2002) "Accumulation of PN1 and PN3 sodium channels in painful human neuroma- evidence from immunocytochemistry" Acta Neurochir (Wien) 144(8): 803-10; discussion 810.). NaV1.6 and NaV1.7 are also expressed in dorsal root ganglion neurons and contribute to the small TTX sensitive component seen in these cells. NaV1.7 in particular my therefore be a potential pain target in addition to it's role in neuroendocrine excitability (See, Klugbauer, N., L. Lacinova, et al. (1995) "Structure and functional expression of a new member of the tetrodotoxin- sensitive voltage-activated sodium channel family from human neuroendocrine cells" Embo J 14(6): 1084-90). [0010] NaVl.l (See, Sugawara, T., E. Mazaki-Miyazaki, et al. (2001) "Navl.l mutations cause febrile seizures associated with afebrile partial seizures." Neurology 57(4): 703-5.) and NaV1.2 (See, Sugawara, T., Y. Tsurubuchi, et al. (2001) "A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction" Proc Natl Acad Sci U S A 98(11): 6384-9) have been linked to epilepsy conditions including febrile seizures. There are over 9 genetic mutations in NaVl.l associated with febrile seizures (See, Meisler, M. H., J. A. Kearney, et al. (2002) "Mutations of voltage-gated sodium channels in movement disorders and epilepsy" Novartis Found Symp 241: 72-81) .[0011] Antagonists for NaV1.5 have been developed and used to treat cardiac arrhythmias. A gene defect in NaVl.5 that produces a larger noninactivating component to the current has been linked to long QT in man and the orally available local anesthetic mexilitine has been used to treat this condition (See, Wang, D. W., K. Yazawa, et al. (1997) "Pharmacological targeting of long QT mutant sodium channels." J Clin Invest 99(7): 1714-20).
[0012] Several Na channel blockers are currently used or being tested in the clinic to treat epilepsy (See, Moulard, B.and D. Bertrand (2002) "Epilepsy and sodium channel blockers" . Expert Opin. Ther. Patents 12(1): 85-91.); acute (See, Wiffen, P., S. Collins, et al. (2000) "Anticonvulsant drugs for acute and chronic pain" Cochrane Database Syst Rev 3), chronic (See, Wiffen, P., S. Collins, et al. (2000) "Anticonvulsant drugs for acute and chronic pain" Cochrane Database Syst Rev 3, and Guay, D. R. (2001) "Adjunctive agents in the management of chronic pain" Pharmacotherapy 21(9): 1070-81), inflammatory (See, Gold, M. S. (1999) "Tetrodotoxin-
-6-

\£A2005/042497 PCT/US2004/036297
resistant Na+ currents and inflammatory hyperalgesia." Proc Natl Acad Sci U S A 96(14): 7645-
9), and neuropathic pain (See, Strichartz, G. R., Z. Zhou, et al. (2002) "Therapeutic concentrations of local anaesthetics unveil the potential role of sodium channels in neuropathic pain" Novartis Found Symp 241: 189-201, and Sandner-Kiesling, A., G. Rumpold Seitlinger, et al. (2002) "Lamotrigine monotherapy for control of neuralgia after nerve section" Acta Anaesthesiol Scand 46(10): 1261-4); cardiac arrhythmias (See, An, R. H., R. Bangalore, et al. (1996) "Lidocaine block of LQT-3 mutant human Na+ channels" Circ Res 79(1): 103-8, and Wang, D. W., K. Yazawa, et al. (1997) "Pharmacological targeting of long QT mutant sodium channels" J Clin Invest 99(7): 1714-20); neuroprotection (See, Taylor, C. P. and L. S. Narasimhan (1997) "Sodium channels and therapy of central nervous system diseases" Adv Pharmacol 39: 47-98) and as anesthetics (See, Strichartz, G. R., Z. Zhou, et al. (2002) "Therapeutic concentrations of local anaesthetics unveil the potential role of sodium channels in neuropathic pain." Novartis Found Symp 241: 189-201).
[0013] Various animal models with clinical significance have been developed for the study of sodium channel modulators for numerous different pain indications. E.g., malignant chronic pain, see, Kohase, H., et al., Acta Anaesthesiol Scand. 2004; 48(3):382-3; femur cancer pain (see, Kohase, H., et al., Acta Anaesthesiol Scand. 2004; 48(3):382-3); non-malignant chronic bone pain (see, Ciocon, J. O. et al., J Am Geriatr Soc. 1994; 42(6):593-6); rheumatoid arthritis (see, Calvino, B. et al., Behav Brain Res. 1987; 24(l):ll-29); osteoarthritis (see, Guzman, R. E., et al., Toxieol Pathol. 2003; 31(6);619-24); spinal stenosis (see, Takenobu, Y. et al., J.Neurosci Methods., 2001; 104(2):191-8); Neuropathic low back pain(see, Hines, R., et al.,Pain Med. 2002; 3(4):361-5; Massie, J. B., et al., J Neurosci Methods. 2004; 137(2):283-9; neuropathic low back pain (see, Hines, R., et al., Pain Med. 2002; 3(4):361-5; Massie, J. B., et al., J Neurosci Methods. 2004; 137(2):283-9); myofascial pain syndrome (see, Dalpiaz & Dodds, J Pain Palliat Care Pharmacother. 2002; 16(l):99-104; Sluka KA et al., Muscle Nerve. 2001; 24(l):37-46); fibromyalgia (see, Bennet & Tai, Int J Clin Pharmacol Res, 1995;15(3): 115-9); . . temporomandibular joint pain (see, Ime H, Ren K, Brain Res Mol Brain Res. 1999; 67(l):87-97); chronic visceral pain, including, abdominal (see, Al-Chaer, E. D., et al., Gastroenterology. 2000; 119(5):1276-85); pelvic/perineal pain, (see, Wesselmann et al., Neurosci Lett. 1998; 246(2):73-6); pancreatic (see, Vera-Portocarrero, L. B., et al., Anesthesiology. 2003; 98(2):474-84);
. -7-

WO2005/042497 PCT/US2004/036297
IBS pain(see, Verne, G. N., et al.,Pain. 2003; 105(l-2):223-30; La JH et al., World Gastroenterol. 2003; 9(12):2791-5); chronic headache pain (see, Willimas & Stark, Cephalalgia. 2003; 23(10):963-71); migraine (see, Yamamura, H., et al., J Neurophysiol. 1999; 81(2):479-93); tension headache, including, cluster headaches (see, Costa, A., et al., Cephalalgia. 2000; 20(2):85-91); chronic neuropathic pain, including, post-herpetic neuralgia (see, Attal, N., et al., Neurology. 2004; 62(2):218-25; Kim & Chung 1992, Pain 50:355); diabetic neuropathy (see, Beidoun A et al., Clin J Pain. 2004; 20(3):174-8; Courteix, C, et al., Pain. 1993; 53(l):81-8); HIV- associated neuropathy (see, Portegies & Rosenberg, Ned Tijdschr Geneeskd. 2001; 145(15):731-5; Joseph EK et al., Pain. 2004; 107(l-2):147-58; Oh, S. B., et al., J Neurosci. 2001; 21(14):5027-35); trigeminal neuralgia (see, Sato, J., et al., Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 97(l):18-22; Imamura Y et al., Exp Brain Res. 1997; 116(l):97-103); Charcot-Marie Tooth neuropathy (see, Sereda, M., et al., Neuron. 1996; 16(5): 1049-60); hereditary sensory neuropathies (see, Lee, M. J., et al., Hum Mol Genet. 2003; 12(15): 1917-25); peripheral nerve injury (see, Attal, N., et al., Neurology. 2004; 62(2):218-25; Kim & Chung 1992, Pain 50:355; Bennett & Xie, 1988, Pain 33:87; Decostered, I. & Woolf, C. J., 2000, Pain 87:149; Shir, Y. & Seltzer, Z. 1990; Neurosci Lett 115:62); painful neuromas (see, Nahabedian & Johnson, Ann Plast Surg. 2001; 46(l):15-22; Devor & Raber, Behav Neural Biol. 1983; 37(2):276-83); ectopic proximal and distal discharges (see, Liu, X. et al., Brain Res. 2001; 900(1): 119-27); radiculopathy (see, Devers & Galer, (see, Clin J Pain. 2000; 16(3):205-8; Hayashi N et al.. Spine.. 1998; 23(8):877-85); chemotherapy induced neuropathic-pain (see, Aley, K. O., et al., Neuroscience. 1996; 73(l):25?r65); radiotherapy-induced neuropathic pain; post-mastectomy pain (see, Devers & Galer, Clin J Pain. 2000; 16(3):205-8); central pain (Cahana, A., et al., Anesth Analg. 2004; 98(6): 1581-4), spinal cord injury pain (see, Hains, B. C, et al., Exp Neurol. 2000; 164(2):426-37); post-stroke pain; thalamic pain (see, LaBuda, C. J., et al., Neurosci Lett. 2000; 290(l):79-83); complex regional pain syndrome (see, Wallace, M. S., et al., Anesthesiology. 2000; 92(l):75-83; Xantos D et al., J Pain. 2004; 5(3 Suppl 2):S1); phanton pain (see, Weber, W. E., Ned Tijdschr Geneeskd. 2001; 145(17):813-7; Levitt & Heyback, Pain. 1981; 10(l):67-73); intractable pain (see, Yokoyama, M., et al., Can J Anaesth. 2002; 49(8):810-3); acute pain, acute post-operative pain (see, Koppert, W., et al., Anesth Analg. 2004; 98(4):1050-5; Brennan, T. J., et al., Pain. 1996; 64(3):493-501); acute musculoskeletal pain; joint pain (see, Gotoh, S., et al., Ann Rheum Dis. 1993; 52(ll):817-22); mechanical low back pain
-8-

WO2005/042497 PCT/US2004/036297
(see, Kehl, L. J., et al., Pain. 2000; 85(3):333-43); neck pain; tendonitis; injury/exercise pain (see, Sesay, M., et al., Can J Anaesth. 2002; 49(2): 137-43); acute visceral pain, including, abdominal pain; pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hernias; etc (see, Giambernardino, M. A., et al., Pain. 1995; 61(3):459-69); chest pain, including, cardiac Pain (see, Vergona, R. A., et al., Life Sci. 1984; 35(18):1877-84); pelvic pain, renal colic pain, acute obstetric pain, including, labor pain (see, Segal, S., et al., Anesth Analg. 1998; 87(4):864-9); cesarean section pain; acute inflammatory, burn and trauma pain; acute intermittent pain, including, endometriosis (see, Cason, A. M, et al.,Horm Behav. 2003; 44(2):123-31); acute herpes zoster pain; sickle cell anemia; acute pancreatitis (see, Toma, H; Gastroenterology. 2000; 119(5): 1373-81); breakthrough pain; orofacial pain, including, sinusitis pain, dental pain (see, Nusstein, J., et al., J Endod. 1998; 24(7):487-91; Chidiac, J. J., et al., Eur J Pain. 2002; 6(l):55-67); multiple sclerosis (MS) pain (see, Sakurai & Kanazawa, J Neurol Sci. 1999; 162(2): 162-8); pain in depression (see, Greene B, Curr Med Res Opin. 2003; 19(4):272-7); leprosy pain; behcet's disease pain; adiposis dolorosa (see, Devillers & Oranje, Clin Exp Dermatol. 1999; 24(3):240-l); phlebitic pain; Guillain-Barre pain; painful legs and moving toes; Haglund syndrome; erythromelalgia pain (see, Legroux-Crespel, E., et al., Ann Dermatol Venereol. 2003; 130(4):429-33); Fabry's disease pain (see, Germain, D. P., J Soc Biol. 2002;196(2):183-90); Bladder and urogenital disease, including, urinary incontinence (see, Berggren, T., et al., J Urol. 1993; 150(5 Pt 1): 1540-3); hyperactivity bladder (see, Chuang, Y. C, et al., Urology. 2003; 61(3):664-70); painful bladder syndrome (see.Yoshimura, N., et al,, J . Neurdsci. 2001;'21(21):'8690-6); interstitial cyctitis. (IC) (see, Giannakopoulos& Campilornatos, Arch Ital Urol Nefrol Androl. 1992; 64(4):337-9; Boucher, M., et al., J Urol. 2000; 164(l):203-8); and prostatitis (see, Mayersak, J. S., Int Surg. 1998; 83(4):347-9; Keith, I. M., et al., J Urol. 2001; 166(l):323-8).
[0014] Voltage-gated calcium channels are membrane-spanning, multi-subunit proteins that open in response to membrane depolarization, allowing Ca entry from the extracellular milieu. Calcium channels were initially classified based on the time and voltage-dependence of channel opening and on the sensitivity to pharmacological block. The categories were low-voltage activated (primarily T-type) and high-voltage activated (L,N,P,Q or R-type). This classification scheme was replaced by a nomenclature based upon the molecular subunit composition, as summarized in Table I (Hockerman, G. H., et. al. (1997) Annu. Rev. Pharmacol. Toxicol. 37:
-9-

PCT/US2004/036297 WO 2005/042497
361-96; Striessnig, J. (1999) Cell. Phvsiol. Biochem. 9: 242-69). There are four primary subunit types that make up calcium channels - a1, a2d, ß and ? (See, e.g., De Waard et al. Structural and functional diversity of voltage-activated calcium channels. In Ion Channels, (ed. T. Narahashi) 41-87, (Plenum Press, New York, 1996)). The a1 subunit is the primary determinant of the pharmacological properties and contains the channel pore and voltage sensor (Hockerman, G. H., et. al. (1997) Annu. Rev. Pharmacol. Toxicol. 37: 361-96; Striessnig, J. (1999) Cell Physiol. Biochem. 9: 242-69). Ten isoforms of the a1 subunit are known, as indicated in Table I. The a2d subunit consists of two disulfide linked subunits, a2, which is primarily extracellular and a transmembrane d subunit. Four isoforms of a2d are known, a2d-l, a2d-2, a2d-3 and a2d-4. The ß subunit is a non-glycosylated cytoplasmic protein that binds to the a1 subunit. Four isoforms are known, termed ß1 to ß4. The ? subunit is a transmembrane protein that has been biochemically isolated as a component of Cavl and Cav2 channels. At least 8 isoforms are known (?1 to ?8) (Kang. M.G. and K. P. Campbell (2003) J. Biol. Chem. 278: 21315-8). The nomenclature for voltage-gated calcium channels is based upon the content of the a1 subunit, as indicated in Table I. Each type of a1 subunit can associate with a variety of ß, a2d or ? subunits, so that each Cav type corresponds to many different combinations of subunits.

[0016] Cav2 currents are found almost exclusively in the central and peripheral nervous system and in neuroendocrine cells and constitute the predominant forms of presynaptic voltage-gated calcium current. Presynaptic action potentials cause channel opening and neurotransmitter
-10-

WO2005/042497 PCT/US2004/036297
release is steeply dependent upon the subsequent calcium entry. Thus, Cav2 channels play a central role in mediating neurotransmitter release.
[0016] Cav2.1 and Cav2.2 contain high affinity binding sites for the peptide toxins ?-conotoxin-MVIIC and ?-conotoxin-GVIA, respectively, and these peptides have been used to determine the distribution and function of each channel type. Cav2.2 is highly expressed at the presynaptic nerve terminals of neurons from the dorsal root ganglion and neurons of lamina I and II of the dorsal horn (Westenbroek, R. R, et al. (1998) J. Neurosci. 18: 6319-30; Cizkova, D, et al. (2002) Exp. Brain Res. 147:456-63). Cav2.2 channels are also found in presynaptic terminals between second and third order interneurons in the spinal cord. Both sites of neurotransmission are very important in relaying pain information to the brain.
[0017] Pain can be roughly divided into three different types: acute, inflammatory, and neuropathic. Acute pain serves an important protective function in keeping the organism safe from stimuli that may produce tissue damage. Severe thermal, mechanical, or chemical inputs have the potential to cause severe damage to the organism if unheeded. Acute pain serves to quickly remove the individual from the damaging environment. Acute pain by its very nature generally is short lasting and intense. Inflammatory pain, on the other hand, may last for much longer periods of time and its intensity is more graded. Inflammation may occur for many reasons including tissue damage, autoimmune response, and pathogen invasion. Inflammatory pain is mediated by a variety of agents that are released during inflammation, including substance P, histamines; acid, prostaglandin, bradykinin, CGRP,eytokines, ATP, and other agents (Julius, D. and A. I. Basbaum (2001) Nature 413 (6852): 203-10). The third class of pain is neuropathic and involves nerve damage arising from nerve injury or viral infection and results in reorganization of neuronal proteins and circuits yielding a pathologic "sensitized" state that can produce chronic pain lasting for years. This type of pain provides no adaptive benefit and is particularly difficult to treat with existing therapies.
[0018]- Pain, particularly neuropathic and intractable pain is a large unmet medical need. Millions of individuals suffer from severe pain that is not well controlled by current therapeutics. The current drugs used to treat pain include NSAIDS, COX-2 inhibitors, opioids, tricyclic antidepressants, and anticonvulsants. Neuropathic pain has been particularly difficult to treat as it does not respond well to opioids until high doses are reached. Gabapentin is currently the most widely used therapeutic for the treatment of neuropathic pain, although it works in only 60% of
-11-

WO 2005/042497 PCT/US2004/036297
patients and has modest efficacy. The drug is generally safe, although sedation is an issue at higher doses.
[0019] Validation of Cav2.2 as a target for the treatment of neuropathic pain is provided by studies with ziconotide (also known as ?-conotoxin-MVIIA), a selective peptide blocker of this channel (Bowersox, S.S., et al. (1996) J. Pharmacol. EXP. Ther. 279: 1243-9; Jain, K.K. (2000) Exp. Opin. Invest. Drugs 9:2403-10; Vanegas, H. and H. Schaible (2000) Pain 85: 9-18). In man, intrathecal infusion of Ziconotide is effective for the treatment of intractable pain, cancer pain, opioid resistant pain, and neuropathic pain. The toxin has an 85% success rate for the treatment of pain in humans with a greater potency than morphine. An orally available antagonist of Cav2.2 should have similar efficacy without the need for intrathecal infusion. Cav2.1 and Cav2.3 are also in neurons of nociceptive pathways and antagonists of these channels could be used to treat pain.
[0020] Antagonists of Cav2.1, Cav2.2 or Cav2.3 should also be useful for treating other pathologies of the central nervous system that apparently involve excessive calcium entry. Cerebral ischaemia and stroke are associated with excessive calcium entry due to depolarization of neurons. The Cav2.2 antagonist ziconotide is effective in reducing infarct size in a focal ischemia model using laboratory animals, suggesting that Cav2.2 antagonists could be used for the treatment of stroke. Likewise, reducing excessive calcium influx into neurons may be useful for the treatment of epilepsy, traumatic brain injury, Alzheimer's disease, multi-infarct dementia and other classes of dementia,.amyotrophic lateral sclerosis, amnesia, or neuronal damage caused by poison or other toxic substances.
[0021] Cav2.2 also mediates release of neurotransrnitters from neurons of the sympathetic nervous system and antagonists could be used to treat cardiovascular diseases such as hypertension, cardiac arrhythmia, angina pectoris, myocardial infarction, and congestive heart failure.
[0022] However, as described above, the efficacy of currently used sodium channel blockers and calcium channel blockers for the disease states described above has been to a large extent limited by a number of side effects. These side effects include various CNS disturbances such as blurred vision, dizziness, nausea, and sedation as well more potentially life threatening cardiac arrhythmias and cardiac failure. Accordingly, there remains a need to develop additional Na
-12-

WO 2005/042497 PCT/US2004/036297
channel antagonists, and Ca channel antagonists preferably those with higher potency and fewer
side effects.
SUMMARY OF THE INVENTION
[0023] It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels. These compounds have the structure of Formula I:

or a pharmaceutically acceptable salt thereof, wherein RA, Z, Y, r, and W are as defined below.
These compounds and pharmaceutically acceptable compositions are useful for treating or lessening the severity of a variety of diseases, disorders, or conditions, including, but not limited to, acute, chronic, neuropathic, or inflammatory pain such as femur cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; neuropathic low back pain; myofascial pain syndrome; fibromyalgia; temporomandibular joint pain; chronic visceral pain, including, abdominal; pancreatic; IBS pain; chronic headache pain; migraine; tension headache, including, cluster headaches; chronic neuropathic pain, including, post-herpetic. neuralgia; diabetic neuropathy; HIV-.associated neuropathy; trigeminal neuralgia; Charcot-Marie Tooth neuropathy; hereditary sensory neuropathies; peripheral nerve injury; painful neuromas;
ectopic proximal and distal discharges; radiculopathy; chemotherapy induced neuropathic pain; radiotherapy-induced neuropathic pain; post-mastectomy pain; central pain; spinal cord injury pain; post-stroke pain; thalamic pain; complex regional pain syndrome; phantpn pain; intractable pain; acute pain, acute post-operative pain; acute musculoskeletal pain; joint pain; mechanical low back pain; neck pain; tendonitis; injury/exercise pain; acute visceral pain, including, abdominal pain; pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hennas; etc; chest pain, including, cardiac Pain; pelvic pain, renal colic pain, acute obstetric pain, including, labor pain; cesarean section pain; acute inflammatory, burn and trauma pain; acute intermittent
-13-

WO 2005/042497 PCT/US2004/036297
pain, including, endometriosis; acute herpes zoster pain; sickle cell anemia; acute pancreatitis; breakthrough pain; orofacial pain, including, sinusitis pain, dental pain; multiple sclerosis (MS) pain; pain in depression; leprosy pain; behcet's disease pain; adiposis dolorosa; phlebitic pain; Guillain-Barre pain; painful legs and moving toes; Haglund syndrome; erythromelalgia pain; Fabry's disease pain; bladder and urogenital disease, including, urinary incontinence; hyperactivity bladder; painful bladder syndrome; interstitial cyctitis (IC); or prostatitis, arthritis, migrane, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, and incontinence.
DETAILED DESCRIPTION OF THE INVENTION
1. General Description of Compounds of the Invention:
[0024] The present invention provides a compound of Formula I:



or apharmaceutically acceptable salt thereof, wherein:
r is 0 to 4;
Z is O, N or CH;
Y and W are independently selected from hydrogen, Formula Ia:


wherein:

-14-

.WO 2005/042497 PCT/US2004/036297

wherein:
T is a bond or a C1-6 straight or branched aliphatic chain wherein a methylene unit
of T is optionally replaced by a C3-8 cycloaliphatic group; U is-CH2-or-CH2-CH2-; X is N-C1-4 alkyl, NH, O, S, S(O), or SO2; and each occurrence of Rc is independently M-Rx; wherein:
M is a bond or is a C1-6 alkylidene chain wherein up to two non-adjacent methylene units of M are optionally replaced by C(O), CO2, C(O)C(O), C(O)NR, OC(O)NR, NRNR, NRNRC(O), NRC(O), NRCO2, NRC(O)NR, S(O), SO2, NRSO2, SO2NR, NRSO2NR, O, S, or NR, and Rx is R', halogen, NO2, or CN; wherein:
each occurrence of R' is independently selected from hydrogen or an optionally substituted group selected from C1-8 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring • ¦ having 3-10 ring atoms, or R and R' taken together with the atbm(s) to which they are boundj or two .occurrences of R' taken together with the atom(s) to which they are bound, form a 5-8 membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
V is a bond, -C(O)-, or-S(O)2-; ¦ Q is a bond or a C1-4 alkylidene chain wherein up to two non-adjacent methylene units of
Q are optionally replaced by -O-, -NH-, or -S-; m is 0 or 1;
Ring E is C6-10 aryl. a 5-10 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 3-10 membered
-15-

WO 005/042497 PCT/US2004/036297
heterocyclyl ring having 1-4 heteroatoms independently selected from nitrogen,
oxygen, or sulfur; and s is 0 to 8; or Formula Ib:
wherein:
D is -C1-6alkyl- or a bond; and t is 0 to 5; each occurrence of R is independently selected from hydrogen or an optionally substituted C1-6
aliphatic group; and
each occurrence of RA, RB and RD are independently selected from R1, R2, R3, R4 or R5, wherein:
R1 is oxo, R6 or (C1-4aliphatic)n-J, wherein: n isO or l;
J is halo, CN, NO2, CF3, OCF3, OH, SR6, S(O)R6, SO2R6, NH2, NHR6, N(R6)2, NR6R8, C(O)OH, C(O)0R6 or OR6; or:
two Rl on adjacent ring atoms, taken together, form 1,2-methylenedioxy or 1,2-
ethyleneciioxy;
R2 is C1-6aliphatic, optionally substituted with up to two substituents independently selected from R1, R4, or R5;
R3 is C3-8cycloaliphatic, C6-10 aryl. a 5-10 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 3-10. membered heterocyclyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R3 is optionally substituted with up to three substituents independently selected from Rl, R2, R4 or R5;
-16-

WO 2005/042497 PCT/US2004/036297
' i
R4 is OR5, OR6, OC(O)R6, OC(O)R5, OC(O)OR6, OC(O)OR5, OC(O)N(R6)2, OC(O)N(R5)2, OC(O)N(R6R5), SR6, SR5, S(O)R6, S(O)R5, SO2R6, SO2R5, SO2N(R6)2 SO2N(R5)2, SO2NR5R6, SO3R6, SO3R5, C(O)R5, C(O)OR5, C(O)R6, C(O)OR6, C(O)N(R6)2, C(O)N(R5)2, C(O)N(R5R6), C(O)N(OR6)R6, C(O)N(OR5)R6, C(O)N(OR6)R5, C(O)N(OR5)R5, C(NOR6)R6, C(NOR6)R5, C(NOR5)R6, C(NOR5)R5, N(R6)2, N(R5)2, N(R5R6)5 NR5C(O)R5, NR6C(O)R6,
NR6C(O)R5, NR6C(O)OR6, NR5C(O)OR6, NR6C(O)OR5, NR5C(O)OR5, NR6C(O)N(R6)2 NR6C(O)NR5R6, MR.6C(O)N(R5)2, NR5C(O)N(R6)2, NR5C(O)NR5R6, NR5C(O)N(R5)2, NR6SO2R6, NR6SO2R5, NR5SO2R5, NR6SO2N(R6)2, NR6SO2NR5R6, NR6SO2N(R5)2, NR5SO2NR5R6, NR5SO2N(R5)2, N(OR6)R6, N(OR6)R5, N(OR5)R5, or N(OR5)R6;
R5 is a C3-8cycloaliphatic, C6-10 atyl, a 5-10 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 3-10 membered heterocyclyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R5 is optionally substituted with up to three R1 substituents;
R6 is R optionally substituted with R7, wherein:
R7 is a C3-8cycloaliphatic, C6-10 aryl; a 5-10 membered heteroaryl ring having 1-4-heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 3-10 membered heterocyclyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R7 is optionally substituted with up to two substituents independently selected from R, 1,2-methylenedioxy, 1,2-ethylenedioxy, or (CH2)n-G, wherein G is selected from halo, CN, NO2, CF3, OCF3, OH, S-aliphatic, S(O)-aliphatic, SO2-aliphatic, NH2, N-aliphatic,
N(aliphatic)2, N(aliphatic)R8, COOH, C(O)O(-aliphatic, or O-aliphatic; and
R8 is an amino protecting group; provided that only one of Y and W is formula Ia or Ib and the other of Y and W is hydrogen.
-17-

WO2005/042497 PCT/US2004/036297
[0025] In certain other embodiments, for compounds of Formula I as described generally above and herein:
a) when Z is N, W is Formula Ia, A is -C2alkyl-NH-, V is -C(O)-, Q is -C1alkyl-O-, and
Ring E is phenyl, then RA is not hydrogen, -Cl, -Br, C1-4alkyl, methoxy, or nitro, either
singly or in combination;
b) when Z is N, W is Formula Ia, A is -C2alkyl-NH-, V is -C(O)-, Q is a bond, and Ring
E is phenyl, then RA is not hydrogen, -Cl, -Br, C1-4alkyl, methoxy, or nitro, either singly
or in combination;
c) when Z is N, W is Formula la, A is -C3alkyl-NH-, V is -C(O)-, Q is a bond, and Ring
E is phenyl, then RA is not 4-amino, or 4-methoxycarbonyl;
d) when Z is N, W is Formula la, A is -C3alkyl-NH-, V is -C(O)-, and Q is a bond, then
Ring E is not -2(2,3-dihydro-benzo[l,4]dioxine);
e) when Z is N, W is Formula la, A is -C3alkyl-NH-, V is -C(O)-, and Q is a
-Cialkyl-O-, then Ring E is not -6(4-dimethyl-2H-chromen-2-one);
f) when Z is N, W is Formula la, A is -C2alkyl-NH-, V is -C(O)-, and Q is a
-C2alkyl-O-, then Ring E is not unsubstituted phenyl;
g) when Z is N, W is Formula Ia, A is -C2alkyl-NH-, V is -C(O)-, and B is a bond, then
Ring E is not unsubstituted thienyl;
h) when Z is N, W is Formula Ia, A is -C2alkyl-NH-, V is -C(O)-, and Q is a Cialkyl-O-,. and Ring E is phenyl, then RA is not phenyl at the 4 position;
i) when Z is N,W is Fomula Ia A is-C2alkyl-NH-,V is -C(O)-,and Q is a -C2alkyl,
then Ring E is not 2-isoindoline-l,3-dione;
j) when Z is N, W is Formula Ia, A is -C2alkyl-NH-, V is -C(O)-, and Q is a
-C2alkyl-O-, and Ring E is phenyl, then RA is not phenyl at the 4 position; and
k) when Z is N, W is Formula Ia, A is -C2alkyl-NH-, V is -C(O)-, and Q is a bond, then
Ring E is not unsubstituted adamantyl. •¦
[0026] According to another embodiment, the present invention provides a compound of
formula Ia, as defined generally above, wherein:
-18-

WO2005/042497 PCT/US2004/036297
(a) when Z is N, Y is hydrogen, W is formula Ia, A is , and V and Q are each a
bond, then:
(i) when r is 1 and RA is methyl in the C-5 or C-6 position of the benzimidazole ring, then E is not:
unsubstitued phenyl;
phenyl substituted in the ortho position with methyl, OMe, or OEt; or
phenyl substituted in the para position with OMe or methyl; and (ii) when r is 0, then E is not:
unsubstituted phenyl;
unsubstituted naphthyl;
phenyl substituted in the para position with OEt, Br, OH, or OMe;
phenyl substituted in the meta position with chloro; or
phenyl substituted in the ortho position with methyl;
(b) when Z is N, Y is hydrogen, W is formula Ia, Q is -NHCH2-, r is 0, and V is C(O), then:
(i) when A is -CH2CH2NH-, then E is notmd
(ii) when A is -CH2NH-, then E is not
(c) when Z is C, W is hydrogen, Y is formula Ia, r is 0, A is -CH2CH2NH-, V is C(O), Q is
-CH2O- and E is phenyl, then:
(i) s is not 0;
(ii) when s is 1, RB is not:
-19-

WO 2005/042497 PCT/US2004/036297
unsubstituted phenyl, chloro, OMe, methyl, bromo, or
in the para position; cyano or OMe in the ortho position; or methyl in the meta position;
(iii) when s is 2, RB is not dichloro in the ortho/para positions; and (iv) when s is 3, RB is not 2,3,4-trimethyoxy or 2,4,5-trichloro.
[0027] In certain other embodiments, for compounds of Formula I as described generally above and herein:
a) when Z is N, W is Formula la, A is -CH2CH2NH-, V is -C(O)-, Q is -CH2O-, and
Ring E is phenyl, then RA is not -Cl, -Br, C1-4alkyl, methoxy, or nitro, either singly or in
combination;
b) when Z is N, W is Formula la, A is -CH2CH2NH-, V is -C(O)-, Q is a bond, and Ring
E is phenyl, then RA is not -Cl, -Br, C1-4alkyl, methoxy, or nitro, either singly or in
combination;
c) when Z is N, W is Formula Ia, A is -CH2CH2CH2NH-, V is -C(O)-, Q is a bond, and
Ring E is phenyl, then RA is not 4-amino, or 4-methoxycarbonyl;
d) when Z is N, W is Formula Ia; A is -CH2CH2CH2NH-, V is -C(O)-, and Q' is a bond,
¦ ' thenRingEisnot-2(2,3-dihydro-benzo[i,4]dioxine); • ••• •
e) when Z is N, W is Formula Ia, A is -CH2CH2CH2NH-, V is -C(O)-, and Q is a
-CH2O-, then Ring E is not -6(4-dimethyl-2H-chromen-2-one);
f) when Z is N, W is Formula Ia, A is -CH2CH2NH-, V is -C(O)-, and Q is a
-CH2CH2O-, then Ring E is not unsubstituted phenyl;
g)' when Z is N, W is Formula la, A is -CH2CH2NH-, V is -C(O)-, and Q is a bond, then
Ring E is not unsubstituted thienyl;
h) when Z is N, W is Formula la, A is -CH2CH2NH-, V is -C(O), and Q is a -CH2O-,
and Ring E is phenyl, then RA is not phenyl at the 4 position;
i) when Z is N, W is Formula la, A is -CH2CH2NH-, V is -C(O)-, and Q is -CH2CH2-,
then Ring E is not 2-isoindoline-l,3-dione;
-20-

WO3005/042497 PCT/US2004/036297
j) when Z is N, W is Formula la, A is -CH2CH2NH-, V is -C(O)-, and Q is -CH2CH2O-,
and Ring E is phenyl, then RA is not phenyl at the 4 position; and
k) when Z is N, W is Formula la, A is -CH2CH2NH-, V is -C(O)-, and Q is a bond, then
Ring E is not unsubstituted adamantyl.
1) when Z is N, W is Formula Ia, A is -CH2CH2NH-, V is -C(O)-, Q is -CH2CH2O-, and
Ring E is phenyl, then RB is not -Cl, -Br, C1-4alkyl, methoxy, unsubstituted phenyl,
-C(CH3)2phenyl, or nitro, either singly or in combination;
m) when Z is N, W is Formula Ia, A is -CH2CH2NH-, V is -C(O)-, Q is -CH=CH2-, and
Ring E is phenyl, then RB is not -Cl in the ortho position; and
n) when Z is N, W is Formula Ia, A is -CH2CH2NH-, V is -SO2-, Q is a bond, and Ring
E is phenyl, then RB is not chloro.
[0028] Another embodiment of the present invention provides a method of treating or lessening the severity of a disease, disorder, or condition selected from acute, chronic, neuropathic, or inflammatory pain, including femur cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; neuropathic low back pain; myofascial pain syndrome; fibromyalgia; temporomandibular joint pain; chronic visceral pain, including, abdominal; pancreatic; IBS pain; chronic headache pain; migraine; tension headache, including, cluster headaches; chronic neuropathic pain, including, post-herpetic neuralgia; diabetic neuropathy; HIV- associated neuropathy; trigeminal neuralgia; Charcot-Marie Tooth neuropathy; hereditary sensory neuropathies; peripheral nerve.injury; painful neuromas; ectopic proximal and distal discharges; radiculopathy; chemotherapy induced neuropathic pain; radiotherapy-induced neuropathic pain; post-mastectomy pain; central pain; spinal cord injury pain; post-stroke pain; thalamic pain; complex regional pain syndrome; phanton pain; intractable pain; acute pain, acute post-operative pain; acute musculoskeletal pain; joint pain; mechanical low back pain; neck pain; tendonitis; injury/exercise pain; acute visceral pain, including, . abdominal pain; pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hernias; etc; chest pain, including, cardiac Pain; pelvic pain, renal colic pain, acute obstetric pain, including, labor pain; cesarean section pain; acute inflammatory, burn and trauma pain; acute intermittent pain, including, endometriosis; acute herpes zoster pain; sickle cell anemia; acute pancreatitis; breakthrough pain; orofacial pain, including, sinusitis pain, dental pain; multiple sclerosis (MS) pain; pain in depression; leprosy pain; behcet's disease pain;
-21-

WO 2005/042497 PCT/US2004/036297
adiposis dolorosa; phlebitic pain; Guillain-Barre pain; painful legs and moving toes; Haglund syndrome; erythromelalgia pain; Fabry's disease pain; bladder and urogenital disease, including, urinary incontinence; hyperactivity bladder; painful bladder syndrome; interstitial cyctitis (IC); or prostatitis; arthritis, migrane, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or an epilepsy condition, a neurodegenerative disorder, a psychiatric disorder such as anxiety and depression, myotonia, arrythmia, a movement disorder, a neuroendocrine disorder, ataxia, multiple sclerosis, irritable bowel syndrome, or incontinence comprising the step of administering to said patient an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein RA, Z, Y, r, and W are as defined above
and in classes and subclasses as desribed herein.
[0029] A preferred aspect of the present embodiment is where the disease, condition, or
disorder is acute, chronic, neuropathic, or inflammatory pain.
[0030] Another embodiment of the present invention provides a method for treating or
lessening the severity of a disease, condition or disorder wherein the disease, condition, or •
disorder is implicated, in the activation, of voltagergated. sodium channels comprising
administering an effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein RA, Z, Y, r, and W are as defined above and in classes and subclasses as desribed herein.
[0031] A preferred aspect of the present embodiment is where the disease, condition, or disorder is acute, chronic, neuropathic, or inflammatory pain, epilepsy or an epilepsy condition, a
-22-

WO2005/042497 PCT/US2004/036297
neurodegenerative disorder, a psychiatric disorder such as anxiety and depression, myotonia,
arrythmia, a movement disorder, a neuroendocrine disorder, ataxia, multiple sclerosis, irritable
bowel syndrome, or incontinence.
[0032] A particularly preferred aspect of the present embodiment is where the disease,
condition, or disorder is acute, chronic, neuropathic, or inflammatory pain.
[0033] Another preferred aspect of the present embodiment is where the method comprises
an additional therapeutic agent.
[0034] Yet another embodiment of the present invention provides a method of inhibiting NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 activity in:
(a) a patient; or
(b) a biological sample;
which method comprises administering to said patient, or contacting said biological sample with a compound of Formula I:
ora pharmaceutically acceptable salt mefeof, .wherein RA, Z, Y,.r, andWare as defined above and in classes and subclasses as desribed herein.
2. Compounds and Definitions:
[0035] Compounds of this invention include those described generally above, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75* Ed. Additionally, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, M.B. and
-23-

WO 2005/042497 PCT/US2004/036297
March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
[0036] The present invention provides compounds of Formula I with substituents that are monovalent, such as RA, RB, Rc and RD; or divalent, such as A, B, and D. Those skilled in the art will appreciate that for asymmetric divalent substituent groups, such as -C1-6alkyl-NH-, and -C1-4alkyl-O-, there are two possible orientations relative to the parent structure. As used within the present specification, the orientation of a divalent substituent is set by its left/right orientation relative Formula I as taught in the present specification. Those skilled in the art will also appreciate that this orientation convention is not relevant to symmetrical divalent substituents, such as -C(O)-, or -Q-galkyl-.
[0037] For example for Formula I, where Z is N, W is present as Ia, RA is hydrogen, V is -C(O)-, Ring E is phenyl, RB is hydrogen; and A and Q are divalent substituents (A is -C3alkyl-NH-, and Q is -Cialkyl-O-), the following is the described compound.

[0038] For example for Formula I, where Z is N, W is present as Ia, RA is hydrogen, V is
-C(O)-, Ring E is phenyl, RB is hydrogen; and A and Q are divalent substituents (A is
-C2aikyl-NH- and Q is -O—C1alkyl-), the following is the described compound. • . • .

[0039] For example for Formula I, where Z is N, W is present as Ia, U is -CH2-, RA is hydrogen, V is -C(O)-, Ring E is phenyl, RB is hydrogen; and A and Q are divalent substituents
(A is and Q is -C1alkyl-O-), the following is the described compound.
-24-

WO 2005/042497 PCT/US2004/036297
[0040] As described herein, compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention. It will be appreciated that the phrase "optionally substituted" is used interchangeably with the phrase "substituted or unsubstituted." In general, the term "substituted", whether preceded by the term "optionally" or not, refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable", as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments; a stable compound or chemically feasible compound is one that is not substantially altered when, kept at a temperature of 40°G.pr less, in the absence of moisture or. other chemically reactive conditions, for at least a week.
[0041] The terms "aliphatic", "aliphatic group" or "alkyl" as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic • hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle" "cycloaliphatic" or "cycloalkyl"), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-20 aliphatic carbon atoms, i.e., C1-2oalkyl. In some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms, i.e., C1-10alkyl. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms, i.e.,
-25-

WO 2005/042497 PCT/US2004/036297
C1-8alkyl. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, i.e., C1-6alkyl, and in yet other embodiments aliphatic groups contain 1-4 aliphatic carbon atoms, i.e., C1-4alkyl. In some embodiments, "cycloaliphatic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C3-C8 hydrocarbon or bicyclic C8-C12 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0042] The term "heteroaliphatic", "heterocycle", "heterocyclyl", "heterocycloaliphatic", or "heterocyclic" as used herein means non-aromatic, monocyclic, bicyclic, or tricyclic ring systems in which one or more ring members is an independently selected heteroatom. In some embodiments, the "heterocycle", "heterocyclyl", "heterocycloaliphatic", or "heterocyclic" group has three to fourteen ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the system contains 3 to 7 ring members.
[0043] The term "heteroatom" means one or more of oxygen, sulfur, nitrogen, phosphorus,
or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the
quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for
example N (as-in 3,4-dihydro-2H-pyrrolyl),- NH (as-in pyrrolidinyl) or NR+ (as in N-substituted
' pyrrolidinyl))
[0044] The term "unsaturated", as used herein, means that a moiety has one or more units of unsaturation.
[0045] The term "alkoxy", or "thioalkyl", as used herein, refers to an alkyl group, as previously defined, attached to the principal carbon chain through an oxygen ("alkoxy") or sulfur • ("thioalkyl") atom, for example C1-4alkoxy refers to the alkoxyl group, methoxy, ethyoxy, propoxy, and butoxy, including for propoxy and butoxy, the straight and branched structures, that is i-propoxy and n-propoxy; and n-butoxy, i-butoxy and sec-butoxy. [0046] The terms "haloalkyl", "haloalkenyl" and "haloalkoxy" means alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms. The term "halogen" means F, Cl, Br, or I.
-26-

WO 2005/042497 PCT/US2004/036297


[0047] The term "aryl" used alone or as part of a larger moiety as in "aralkyl", "aralkoxy", or "aryloxyalkyl", refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring". The term "aryl" also refers to heteroaryl ring systems as defined hereinbelow.
[0048] The term "heteroaryl", used alone or as part of a larger moiety as in "heteroaralkyl" or "heteroarylalkoxy", refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members. The term "heteroaryl" may be used interchangeably with the term "heteroaryl ring" or the term "heteroaromatic".
[0049] An aryl (including aralkyl, arallcoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents. Suitable substituents on the unsaturated carbon atom of an aryl or heteroaryl group are selected from halogen; -R°; -OR°; -SR°; 1,2-methylene-dioxy; 1,2-ethylenedioxy; phenyl (Ph) optionally substituted with R°; -O(Ph) optionally substituted with R°; -(CH2)1-2(Ph), optionally substituted with R°; -CH=CH(Ph), optionally substituted with R°; -NO2; -CN; -N(R°)2; -NR°C(O)R°; -NR°C(O)N(R°)2; -NR°CO2R°; -NR°NR°C(O)R°; -NR°NR°C(O)N(R°)2; . -NR°NROCO2R°; -C(O)C(O)R°;- • -C(O)CH2C(O)R°; -CO2R°; -C(O)R°;: -C(0)N(R°)2; -6c(O)N(R°)2; -S(Q)2R°; -SO2N(R°)2; .-S.(O)R°; .-NR°SO2N(RO)2; -NR°S02R0;..-C(=S)N(Ro)2; -C(=NH)-N(R°)2; or -(CH2)o-2NHC(0)R° wherein each independent occurrence of R° is selected from hydrogen, optionally substituted C1-6 aliphatic, an unsubstituted 5-6 membered heteroaryl or heterocyclic ring, phenyl, -O(Ph), or -CH2(Ph), or, notwithstanding the definition above, two independent occurrences of R°, on the same substituent or different substituents, taken together with the atom(s) to which each R° group is bound, form a 3-8-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Optional substituents on the aliphatic group of R° are selected from NH2, NH(C1-4aliphatic), N(C1-4aliphatic)2 halogen, C1-4aliphatic, OH, O(C1-4aliphatic), NO2) CN, CO2H, CO2(C1-4aliphatic), O(haloC1-4 aliphatic), or haloC1-4aliphatic, wherein each of the foregoing C1-4aliphatic groups of R° is unsubstituted.
-27-

WO 2005/042497 PCT/US2004/036297
[0050] An aliphatic or heteroaliphatic group, or a non-aromatic heterocyclic ring may contain one or more substituents. Suitable substituents on the saturated carbon of an aliphatic or heteroaliphatic group, or of a non-aromatic heterocyclic ring are selected from those listed above for the unsaturated carbon of an aryl or heteroaryl group and additionally include the following: =0, =S, =NNHR*, =NN(R*)2, =NNHC(O)R*, =NNHCO2(alkyl), =NNHSO2(alkyl), or =NR*, where each R* is independently selected from hydrogen or an optionally substituted C1-6 aliphatic. Optional substituents on the aliphatic group of R* are selected from NH2, NH(C1-4 aliphatic), N(C1-4 aliphatic)2, halogen, C1-4 aliphatic, OH, O(C1-4 aliphatic), NO2, CN, CO2H, C02(C1-4 aliphatic), O(halo C1-4 aliphatic), or haIo(C1-4 aliphatic), wherein each of the foregoing C1-4aliphatic groups of R* is unsubstituted.
[0051] Optional substituents on the nitrogen of a non-aromatic heterocyclic ring are selected from -R+, -N(R+)2, -C(O)R+, -CO2R+, -C(O)C(O)R+, -C(O)CH2C(O)R+, -SO2R+, -SO2N(R+)2, -C(=S)N(R+)2, -C(=NH)-N(R+)2, or -NR+SO2R+; wherein R+ is hydrogen, an optionally substituted C1-6 aliphatic, optionally substituted phenyl, optionally substituted -O(Ph), optionally substituted -CH2(Ph), optionally substituted -(CH2)1-2(Ph); optionally substituted -CH=CH(Ph); or an unsubstituted 5-6 membered heteroaryl or heterocyclic ring having one to four heteroatoms independently selected from oxygen, nitrogen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R+, on the same substituent or different substituents, taken together with the atom(s) to which each R+ group is bound, form a 3-8-membered jpycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently, selected from nitrogen, oxygen, or sulfur Optional substituents on the aliphatic group or the phenyl ring of R+ are selected from NH2, NH(C1-4 aliphatic), N(C1-4 aliphatic)2, halogen, C1-4 aliphatic, OH, O(C1-4 aliphatic), NO2, CN, CO2H, CO2(C1-4 aliphatic), O(halo C1-4 aliphatic), or halo(C1-4 aliphatic), wherein each of the foregoing C1-4aliphatic groups of R+is unsubstituted. [0052] The term "C1-20alkylidene chain" refers to a straight or branched carbon chain of twenty carbon atoms or less that may be fully saturated or have one or more units of unsaturation and has two points of attachment to the rest of the molecule.
[0053] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical
-28-

WO 2005/042497 PCT/US2004/036297
isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. For example, for compounds of formula I:

wherein Z is N or O, one of ordinary skill would recognize that a suitable tautomer is as depicted above. When the Z group of formula I is CH, one of ordinary skill would recognize that a suitable tautomer is as depicted below:

[0054] Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are . within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.
3. Description of Exemplary Compounds:
[0055] In certain embodiments, the present invention provides a compound of formula I
wherein V is -S(O)2-.
[0056] In other embodiments, the present invention provides a compound of formula I
wherein V is -C(O)-.
[0057] In one embodiment, T is a C1-6 straight or branched aliphatic chain wherein a
methylene unit of T is optionally replaced by a C3-6 cycloaliphatic group.
[0058] Also preferred is a compound of formula I wherein Ring E is phenyl.
[0059] Also preferred is a compound of formula I wherein Ring E is. naphthyl.
-29-

WO 2005/042497 PCT/US2004/036297
[0060] Also preferred is a compound of formula I wherein Ring E is pyridinyl.
[0061] Also preferred is a compound of formula I wherein Ring E is thienyl.
[0062] Also preferred is a compound of formula I wherein Ring E is furanyl.
[0063] Also preferred is a compound of formula I wherein Ring E is quinolinyl.
[0064] Also preferred is a compound of formula I wherein Ring E is benzofuranyl.
[0065] Also preferred is a compound of formula I wherein Ring E is 3,4-dihydro-2H-
chromene.
[0066] Also preferred is a compound of formula I wherein Ring E is
2,3-dihydrobenzo[b] [ 1,4]dioxine.
[0067] According to one aspect, the present invention provides a compound of formula I,
wherein Ring E is a preferred group as described above and said group is in combination with
the remaining variables of formula I as set forth in the classes and subclasses described herein.
[0068] In certain embodiments, each RA of formula I, when present, is independently R6,
OR6, CN, or halo. In other embodiments, each RB of formula I, when present, is independently
OR6, N(R6)2> NR6C(O)R6, halo, R6, C(O)R6, or NO2.
[0069] In other embodiments, the A moiety of formula I, when present, is -T-NR6-, wherein
T is a C1-6 straight or branched aliphatic chain. Such A moieties include -CH2CH2N(CH3)-,
-CH2CH2NH-, -CH2NH-, and -CH2CH(CH3)NH-.
[0070] In certain embodiments, the present invention provides a compound of formula I
wherein A is.-T-NH- wherein T is a C1-6 straightor branched aliphatic chain wherein a
methylene unit of T is replaced by a C3-6 cycloaliphatic group. Such cycloaliphatic groups.
include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl groups.
[0071] In other embodiments, the Q moiety of formula I is a C1-4 alkylidene chain wherein
one methylene unit of Q is replaced by -O-, -NH-, or -S-. Such Q moieties of formula I include
-CH2CH2O-, -CH2O-, -OCH2-, -OCH2CH2-, -CH(CH3)O-, -NHCH2-, -C(CH3)2O-, and -CH2S-.
[0072] As described above, for compounds of the invention of Formula I, Z is O,N or C.
Accordingly, in certain embodiments, where Z is N, the corresponding compounds have the
structure of Formula II;
-30-

WO 2005/042497 PCT/US2004/036297

[0073]. In certain embodiments of Formula II, Y is hydrogen, Ring E is phenyl, and W is formula Ia, wherein V is -C(O)-. as shown in Formula Ha:

or a pharmaceutically acceptable salt thereof, wherein RA, r, A, Q, RB, and s are as defined above
and herein.
[0074] Preferred is a compound of Formula Ha, wherein Q is a bond or a C1-4 alkylidene
chain wherein one methylene unit of Q is replaced by -O-, -NH-, or -S-. Such Q moieties of
formula Ila include -CH2CH2O-, -CH2O-, -OCH2-, -OCH2CH2-, -CH(CH3)O-, -NHCH2-,
-C(CH3)2O-,and-CH2S-.
[0075] Particularly preferred is a compound of Formula Ha, wherein Q is -CH2O-.
4
[0076] Also particularly preferred is a compound of Formula Ila, wherein Q is -OCH2-. [0077] Also particularly preferred is a compound of Formula Ila, wherein Q is -NHCH2-. [0078] Also preferred is a compound of Formula IIa, wherein A is -C1-6alkyl -NH-. [0079] Particularly preferred is a compound of Formula Ila, wherein A is -CH2CH2NH-. [0080] Also particularly preferred is a compound Formula IIa, wherein A is -CH2NH-. [0081] In certain embodiments, the present invention provides a compound of formula IIa, wherein A is -CH2CH2NH-, Q is -CH2O-, and each RB is independently C1-6 aliphatic, -CHO, or halogen. In other embodiments, the present invention provides a compound of formula IIb, wherein A is -CH2CH2NH-, Q is -CH2O-, and each RB is inependently methyl, -CHO, fluoro, or chloro.
[0082] In other embodiments, the present invention provides a compound of formula IIa, wherein A is -CH2CH2NH-, Q is -CH=CH-, -CH2O- or -NHCH2 and each RB is independently
-31-

WO 2005/042497 PCT/US2004/036297

CN, C1-6 aliphatic, -N(R6)2, or halogen. Such RB groups include methyl, ethyl, butyl, isopropyl, chloro, fluoro, bromo, N(Me)2, CF3 and -CH2phenyl. According to another embodiment, the present invention provides a compound of formula IIa wherein the benzo ring is substituted at one of, or both of, the C-4- and C-5 positions with tert-butyl, fluoro, or methyl. [0083] According to another embodiment, the present invention provides a compound of formula IIa, wherein A is -CH2CH2NH- or -CH(CH3)NH-, Q is -CH2O- and each RB is independently C1-6 aliphatic, -N(R6 )2, -C(O)R6, or halogen. Such RB groups include methyl, chloro, bromo, ethyl, N(Me)2, -C=CH and C(O)CH3.
[0084] Yet another embodiment of the present invention relates to a compound of formula
Ha, wherein A is -CH2CH2NH-, Q is -CH2O-, -NHCH2-, or -CH(CH3)O-, and each RB is
independently C1-6 aliphatic, -OR6, or halogen. Such RB groups include methyl, ethyl,OMe,
chloro, bromo, and fluoro.
[0085] According to still another embodiment, the present invention provides a compound of formula IIa, wherein A is -CH2CH2NH- or -CH2CH(CH3)NH-, Q is -CH2O, -NHCH2-, -NH-, -CH(CH3)O-, or -C(CH3)2O-, and each RB is independently C1-6 aliphatic, -OR6, or halogen. Such RB groups include methyl, ethyl, -OMe, chloro, bromo, and fluoro. According to another embodiment, the present invention provides a compound of formula IIa wherein r is 2, each RA is fluoro.and is present at the C-4- and C-5 positions.
[0086] In certain embodiments, the present invention provides a compound of formula IIa, wherein A is -CH2CH2NH-, Q is -CH2O-, and each RB is independently C1-6 aliphatic or halogen. In other embodiments, the present invention provides a compound of formula IIa, wherein A is -CH2CH2NH-, Q is -CH2O-, and each RB is inependently methyl, isopropyl, fluoro, bromo, or chloro. In still other embodiments, the present invention provides a compound of formula IIa, wherein A is -CH2CH2NH-, Q is -CH2O-, and each RB is inependently methyl, fluoro, or chloro. In yet other embodiments, the present invention provides a compound of formula Ha, wherein A is -CH2CH2NH-, Q is -CH2O-, and each RB is inependently methyl, bromo, or chloro.
[0087] Also preferred is a compound of Formula Ila, wherein A is

WO 2005/042497 PCT/US2004/036297
[0088] Also preferred is a compound of Formula Ila, wherein A is
[0089]. ¦ Also preferred is a compound of Formula Ila, wherein A is wherein U is -CH2- or -CH2CH2-.
[0090] In certain embodiments of Formula II, Y is hydrogen, Ring E is phenyl, W is Formula Ib and D is a bond, as shown below as formula IIb.

or a pharmaceutically acceptable salt thereof, wherein RA, r, RD, and s are as defined above and
herein.
[0091] Preferred is a compound of Formula IIb, wherein RA is R6 or halo. In certain
embodiments, RA is methyl, chloro or bromo.
[0092] Particularly preferred is a compound of Formula IIb, wherein RA is methyl.
[0093] Also preferred is a compound of Formula IIb wherein RD is halo, OR6, N(R6)2,
NR6C(O)R6, or two RD are taken together to form a methylenedioxy or ethylenedioxy group. In
certain embodiments, RD is -OH, -N(Et)2, -OMe, -NHC(O)CH3, fluoro, or chloro.
[0094] According to another embodiment, the present invention provides a compound of
formula HI:
-33-

or a pharmaceutically acceptable salt thereof, wherein A, Q, RA, r, RB, and s are as defined above
and herein.
[0095] In certain embodiments, each RA of formula III, when present, is independently R6,
OR6, CN, or halo. In other embodiments, each RB of formula III, when present, is independently
OR6, N(R6)2) NR6C(O)R6, halo, R6, C(O)R6, orNO2.
[0096] In other embodiments, the Q moiety of formula III is a C1-4 alkylidene chain wherein
one methylene unit of Q is replaced by -O-, -NH-, or -S-. Such Q moieties of formula III
include -CH2CH2O-, -CH2O-, -OCH2-, -OCH2CH2-, -CH(CH3)O-, -NHCH2-, -C(CH3)2O-, and
-CH2S-.
[0097] In other embodiments, the A moiety of formula III, when present, is -T-NR6-,
wherein T is a C1-6 straight or branched aliphatic chain. Such A moieties include
-CH2CH2N(CH3)-, -CH2CH2NH-, -CH2NH-, and -CH2CH(CH3)NH-;
[0098] In certain embodiments, the present invention provides a compound of formula III
wherein A is -T-NH- wherein T is a C1-6 straight or branched aliphatic chain wherein a
methylene unit of T is replaced by a C3-6 cycloaliphatic group. Such cycloaliphatic groups
include cyclobutyl, cyclopentyl, and cyclohexyl groups.
[0099] According to another embodiment, the present invention provides a compound of
formula IV:
or a pharmaceutically acceptable salt thereof, wherein V, Q, RA, r, RB, n, and s are as defined
above and herein.
[00100] In certain embodiments, each RA of formula IV, when present, is independently R6,
OR6, CN, or halo. In other embodiments, each RB of formula IV, when present, is independently
OR6, N(R6)2) NR6C(O)R6, halo, Rs, C(O)R6, or NO2.
[00101] In other embodiments, the Ring E group of formula IV is phenyl or a 5-6 membered
heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur,
-34-

WO 2005/042497 PCT/US2004/036297
or a 3-7 membered monocyclic heterocyclyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such Ring E groups of formula IV include pyridyl, thienyl, furyl, and pyrazolyl.
[00102] In still other embodiments, the Ring E group of formula IV is an 8-10 membered bicyclic aryl ring or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such Ring E groups of formula IV include naphthyl, quinolinyl, 3,4-dihydro-2H-chromene, and 2,3-dihydrobenzo[b][l,4]dioxine. [00103] In other embodiments, the Q moiety of formula IV is a C1-4 alkylidene chain wherein one methylene unit of Q is replaced by -O-, -NH-, or -S-. Such Q moieties of formula IV include -CH2CH2O-, -CH2O-, -OCH2-, -OCH2CH2-, -CH(CH3)O-, -NHCH2-, -C(CH3)2O-, and -CH2S-. [00104] According to another aspect of the present invention, one of V and Q.is, a bond. According to yet another aspect of the present invention, both of V and Q are a bond. [00105] Representative compounds of formula I are set forth in Table 2 below.
-35-

WO 2005/042497 PCT/US2004/036297



36

WO 2005/042497 PCT/US2004/036297






37

WO2005/042497 PCT/US2004/036297


38

WO2005/042497 PCT/US2004/036297



39

WO2005/042497 PCT/US2004/036297


40

WO 2005/042497 PCT/US2004/036297



41

WO 2005/042497 PCT/US2004/036297


42

WO 2005/042497 PCT/US2004/036297


43

WO 2005/042497 . PCT/US2004/036297


44

WO 2005/042497 PCT/US2004/036297


45

WO 2005/042497 PCT/US20O4/036297


46

WO 2005/042497 PCT/US2004/036297


47

WO!2005/042497 PCT/US2004/036297


48


WO 2005/042497 PCT/US2004/036297


49

WO 2005/042497 PCT/US2004/036297


50

WO 2005/042497 PCT/US2004/036297


51

WO 2005/042497 PCT/US2004/036297



52

WO 2005/042497 PCT/US2004/036297


53

WO 2005/042497 PCT/US2004/036297


54

WO 2005/042497 PCT/US2004/036297



55

WO 2005/042497 PCT7US2004/036297


56

WO2005/042497 PCT/US2004/036297



57

WO 2005/042497 PCT/US2004/036297


58


WO 2005/042497 PCT/US2004/036297


59

WO 2005/042497 PCT/US2004/036297


-60-

WO 2005/042497 PCT/US2004/036297



-61-

WO 2005/042497 PCT/US2004/036297


-62-

WO 2005/042497 PCT/US2004/036297


-63-

WO 2005/042497 PCT/US2004/036297


-64-

WO 2005/042497 PCT/US2004/036297



WO2005/042497 PCT/US2004/036297


-66-

WO2005/042497 PCT/US2004/036297


-67-

WO 2005/042497 PCT/US2004/036297


-68-


WO 2005/042497 PCT/US2004/036297


-69-

WO2005/042497 PCT/US2004/036297


-70-

WO 2005/042497 PCT/US2004/036297


-71-

WO 2005/042497 PCT/US2004/036297


-72-

WO 2005/042497 PCT/US2004/036297


-73-

WO 2005/042497 PCT/US2004/036297


-74-

WO2005/042497 PCT/US2004/036297


-75-

WO 2005/042497 PCT/US2004/036297


-76-

WO 2005/042497 PCT/US2004/036297


-77-

WO 2005/042497 PCT/US2004/036297


-78-

WO 2005/042497 PCT/US2004/036297


-79-

WO 2005/042497 PCT/US2004/036297


-80-


WO 2005/042497 PCT/US2004/036297


-81-

WO 2005/042497 PCT/US2004/036297


-82-

WO 2005/042497 PCT/US2004/036297


-83-

WO 2005/042497 PCT/US2004/036297


-84-

WO2005/042497 PCT/US2004/036297


-85-

WO 2005/042497 PCT/US2004/036297


-86-

I
WO2005/042497 ! PCT/US2004/036297


-87-


WO2005/042497 PCT/US2004/036297


-88-

WO 2005/042497 PCT/US2004/036297


-89-

WO2005/042497 PCT/US2004/036297


-90-

WO 2005/042497 PCT/US2004/036297


-91-

WO 2005/042497 PCT/US2004/036297


-92-

PCT/US2004/036297 WO 2005/042497


-93-

PCT/US2004/036297 WO 2005/042497


-94-

WO 2005/042497 PCT/US2004/036297


-95-

WO 2005/042497 PCT/US2004/036297


-96-

WO 2005/042497 PCT/US2004/036297


-97-

WO 2005/042497 PCT/US2004/036297


-98-

WO 2005/042497 PCT/US2004/036297


-99-

WO 2005/042497 PCT/US2004/036297


-100-

WO 2005/042497 PCT/US2004/036297


-101

WO 2005/042497 PCT/US2004/036297


-102-

WO 2005/042497 PCT/US2004/036297


-103-

WO2005/042497 PCT/US2004/036297


-104-

WO 2005/042497 PCT/US2004/036297


-105-

WO 2005/042497 PCT/US2004/036297


-106-

WO 2005/042497 PCT/US2004/036297


-107-

WO 2005/042497 PCT/US2004/036297


-108-

WO 2005/042497 PCT/US2004/036297


-109-

WO 2005/042497 PCT/US2004/036297


-110-


WO 2005/042497 PCT/US2004/036297


-111-

W0 2005/042497 PCT/US2004/036297


-112-

WO 2005/042497 PCT/US2004/036297


-113-

WO 2005/042497 PCT/US2004/036297


-114-

WO 2005/042497 PCT/US2004/036297


-115-

WO 2005/042497 PCT/US2004/036297


-116-

WO 2005/042497 PCT/US2004/036297




WO 2005/042497 PCT/US2004/036297


-118-

WO 2005/042497 PCT/US2004/036297


-119-

WO 2005/042497 PCT/US2004/036297


-120-

WO 2005/042497 PCT/US2004/036297


-121-

WO 2005/042497 PCT/US2004/036297


-122-

WO 2005/042497 PCT/US2004/036297


-123-

WO 2005/042497 PCT/US2004/036297


-124-

WO 2005/042497 PCT/US2004/036297


-125-

WO 2005/042497 PCT/US2004/036297


-126-

WO 2005/042497 PCT/US2004/036297


-127-

WO 2005/042497 PCT/US2004/036297


-128-

WO 2005/042497 PCT/US2004/036297



-129-

WO 2005/042497 PCT/US2004/036297


-130-

WO 2005/042497 PCT/US2004/036297


-131-

WO 2005/042497 PCT/US2004/036297


-132-

WO 2005/042497 PCT/US2004/036297


133-

WO 2005/042497 PCT/US2004/036297


-134-

WO 2005/042497 PCT/US2004/036297


-135-

WO 2005/042497 PCT/US2004/036297


-136-

WO 2005/042497 PCT/US2004/036297


-137-

WO 2005/042497 PCT/US2004/036297


-138-

WO 2005/042497 PCT/US2004/036297


-139-

WO 2005/042497 PCT/US2004/036297


-140-

WO 2005/042497 PCT/US2004/036297


-141-

WO 2005/042497 PCT/US2004/036297


-142-

WO 2005/042497 PCT/US2004/036297


-143-

WO 2005/042497 PCT/US2004/036297


-144-

WO 2005/042497 PCT/US2004/036297


-145-

WO 2005/042497 PCT/US2004/036297


-146-

WO 2005/042497 PCT/US2004/036297


-147-

WO 2005/042497 PCT/US2004/036297


-148-

WO 2005/042497 PCT/US2004/036297


-149-

WO 2005/042497 PCT/US2004/036297


-150-

WO 2005/042497 PCT/US2004/036297


-151-

WO 2005/042497 PCT/US2004/036297


-152-

WO 2005/042497 PCT/US2004/036297
















-153-

WO 2005/042497 PCT/US2004/036297


154

WO 2005/042497 PCT/US2004/036297


-155-

WO 2005/042497 PCT/US2004/036297


-156-

WO 2005/042497 PCT/US2004/036297


-157-

WO 2005/042497 PCT/US2004/036297


-158-

WO 2005/042497 PCT/US2004/036297


-159-

WO 2005/042497 PCT/US2004/036297


-160-

WO 2005/042497 PCT/US2004/036297


-161-

WO 2005/042497 PCT/US2004/036297


-162-

WO 2005/042497 PCT/US2004/036297


-163-

WO 2005/042497 PCT/US2004/036297


-164-

WO 2005/042497 PCT/US2004/036297


-165-

WO 2005/042497 PCT/US2004/036297


-166-

WO 2005/042497 PCT/US2004/036297


-167-

WO 2005/042497 PCT/US2004/036297


-168-

WO 2005/042497 PCT/US2004/036297


-169-

WO 2005/042497 PCT/US2004/036297


-170-

WO 2005/042497 PCT/US20O4/036297


-171-

WO 2005/042497 PCT/US2004/036297


-172-

WO 2005/042497 PCT/US2004/036297


-173-

WO 2005/042497 PCT/US2004/036297


-174-

WO 2005/042497 PCT/US2004/036297


-175-

WO 2005/042497 PCT/US2004/036297


-176-

WO 2005/042497 PCT/US2004/036297


-177-

WO 2005/042497 PCT/US2004/036297


-178-

WO 2005/042497 PCT7US2004/036297


-179-

WO 2005/042497 PCT/US2004/036297


-180-

WO 2005/042497 PCT/US2004/036297


-181-

WO 2005/042497 PCT/US2004/036297


-182-

WO 2005/042497 PCT/US2004/036297


-183-

WO 2005/042497 PCT/US2004/036297


-184-

WO 2005/042497 PCT/US2004/036297


-185-

WO 2005/042497 PCT/US2004/036297


-186-

WO 2005/042497 PCT/US2004/036297


-187-

WO 2005/042497 PCT/US2004/036297


-188-

WO 2005/042497 PCT/US2004/036297


-189-

WO 2005/042497 PCT/US2004/036297


-190-

WO 2005/042497 PCT/US2004/036297


-191-

WO 2005/042497 PCT/US2004/036297


-192-

WO 2005/042497 PCT/US2004/036297


-193-

WO 2005/042497 PCT/US2004/036297


-194-

WO 2005/042497 PCT/US2004/036297


-195-

WO 2005/042497 PCT/US2004/036297


-196-

WO 2005/042497 PCT/US2004/036297


-197-

WO 2005/042497 PCT/US2004/036297


-198-

WO 2005/042497 PCT/US2004/036297


-199-

WO 2005/042497 PC17US2004/036297


-200-

WO 2005/042497 PCT/US2004/036297


-201-

WO 2005/042497 PCT/US2004/036297
[00106] Although certain exemplary embodiments are depicted and described above and herein, it will be appreciated that a compounds of the invention can be prepared according to the methods described generally above using appropriate starting materials by methods generally available to one of ordinary skill in the art.
4. General Synthetic Methodology:
[00107] The compounds of this invention may be prepared in general by methods known to those skilled in the art for analogous compounds, as illustrated by the general schemes below, and the preparative examples that follow. Starting materials are commercially available from typical chemical reagent supply companies, such as, Aldrich Chemicals Co., Sigma Chemical Company and the like. Compounds that are not commercially available can be prepared by one of ordinary skill in art following procedures set forth in references such as, "Fieser and Fieser's Reagents for Organic Synthesis", Volumes 1-15, John Wiley and Sons, 1991; "Rodd's Chemistry of Carbon Compounds", Volumes 1-5 and Supplementals, Elservier Science Publishers, 1989; and "Organic Reactions", Volumes 1-40, John Wiley and Sons, 1991.
Scheme 1
[00108] Scheme 1 teaches the general preparation of compounds of Formula I. Typically
compounds of Formula I, where Y or W is

wherein A is -NH-, or -N(C1-6alkyl)- are prepared by the coupling of optionally substituted compounds of Formula A, which has a nucleophilic function with optionally substituted compounds of Formula B, which have a terminal electrophilic functionality, such as a carboxylic acid, sulfonyl halide, isocyanate, or the like, as defined previously. These methods are also applicable to compounds of Formulas II and III as defined previously.
-202-

-203-
WO 2005/042497 PCT/US2004/036297


WO 2005/042497 PCT/US2004/036297
SyntheticScheme 2a, 2b:
-204-
[00109] Scheme 2a teaches the preparation of optionally substituted benzimidazole compounds of Formula II. Scheme 2b teaches the preparation of additional optionally substituted benzimidazole compounds of formula II.


WO 2005/042497 PCT/US2004/036297

Scheme 2b
An optionally substituted 1,2-diaminobenzene is reacted with an optionally substituted carboxylic acid with a protected nucleophilic group to provide the benzimidazole intermediate, which is then cyclized to form the benzimidazole moiety. The nucleophilic group is deprotected and acylated, sulfonylated, carbamoylated, or alkylated to provide compounds of Formula II.
-205-

WO 2005/042497 PCT/US2004/036297
Synthetic Scheme 3a. 3b, 3c:
[00110] Scheme 3a teaches the preparation of optionally substituted aryloxy acids. Optionally substituted aryloxy acids are prepared by reacting optionally substituted phenolic compounds with optionally substituted halo-substituted alkyl esters (X is Cl, Br or I) to obtain the corresponding ester.

The ester compound is then hydrolyzed to obtain a desired optionally substituted compound of Formula B.

Scheme 3b
As taught in Schemes 1, 2a, and 2b, compounds of Formula A and B are reacted together to obtain compounds of Formula I. For example, Formula A as taught in Scheme 2b and Formula B as taught in the present Scheme 3b can be reacted to form the corresponding compound of ' Formula I (Scheme 3c).
-206-

WO 2005/042497 PCT/US2004/036297



Synthetic Scheme 4:
[00111] Following the procedures taught in Schemes 1, 2a, 2b, 3a, 3b, and 3c, and using an
optionally substituted aryl isocyanate compound of Formula B,


optionally substituted compounds of Formula I are obtained. Synthetic Scheme 5:
-207-

WO 2005/042497 PCT/US2004/036297
[00112] Following the procedures taught in Schemes 1, 2a, 2b, 3a, 3b, and 3c, and using an optionally substituted aryl sulfonyl chloride compound of Formula B,

optionally substituted compounds of Formula I are obtained.
Synthetic Sclieme 6:
[00113] Protected optionally substituted benzimidazoles of Formula A are prepared by reacting a starting cyano substituted benzimidazole with (Boc)2O followed by reduction of the cyano group (Raney-Nickel/H2 or the like) to provide the desired compound of Formula A.

As taught previously in Schemes 1,2a, 2b, 3a, 3b, 3c, 4 and 5, compounds of Formula A from the present Scheme 6 are derivatized to provide the corresponding compounds of Formula I. Synthetic Schemes 7a, 7b:
-208-

WO 2005/042497 PCT/US2004/036297
[00114] An optionally substituted benzyl alcohol is reacted with phosgene to provide an optionally substituted compound of Formula B.

This compound is then reacted with a compound of Formula A to provide the corresponding compound of Formula I. For example, where the compound of Formula A is a benzimidazole taught in Scheme 2, the following compounds of Formula I, where s is 0 to 4, and m is 1 or 4, as it corresponds to Q where Q is -O-C1-4alkyl are obtained.

Synthetic Scheme 8:.
[00115] A compound of Formula I, where W is

-209-

WO 2005/042497 PCT/US2004/036297
is prepared by reacting an optionally substituted di-amino benzene with an optionally substituted benzaldehyde or benzoic acid to obtain the corresponding optionally substituted compound of Formula I, where RA, RD, r and t are as taught for Formula I, in a manner analogous to Schemes 2a and 2b.
[00116] Although certain exemplary embodiments are depicted and described above and herein, it will be appreciated that a compounds of the invention can be prepared according to the methods described generally above using appropriate starting materials by methods generally available to one of ordinary skill in the art.
5. Uses, Formulation and Administration
[00117] In yet another aspect, a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain, arthritis, migrane, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, or incontinence is provided comprising administering an effective amount of a compound, or a pharmaceutically acceptable composition comprising a compound to a subject in need thereof. In certain preferred embodiments, a method for the treatment or lessening the severity pf acute, chronic, neuropathic, or inflammatory pain is. provided comprising administering an effective amount of a compound or a pharmaceutically acceptable composition' -to a subject in need thereof. In certain embodiments of the present invention an "effective amount" of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of acute, chronic, neuropathic, or inflammatory pain, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, or incontinence. [00118] As described generally above, the compounds of the invention are useful as inhibitors of voltage-gated sodium ion channels or calcium channels, preferably N-type calcium channels. In one embodiment, the compounds and compositions of the invention are inhibitors of one or
-210-

WO 2005/042497 PCT/US2004/036297
more of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2, and thus, without wishing to be bound by any particular theory, the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaVl .5, NaV1.6, NaVl,7, NaVl.8, NaVl.9, or CaV2.2 is implicated in the disease, condition, or disorder. When activation or hyperactivity of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2, is implicated in a particular disease, condition, or disorder, the disease, condition, or disorder may also be referred to as a "NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2-mediated disease, condition or disorder" or a "CaV2.2-mediated condition or disorder". Accordingly, in another aspect, the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 is implicated in the disease state.
[00119] The activity of a compound utilized in this invention as an inhibitor of NaVl.l, NaV1.2, NaV1.3, NaVl.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 may be assayed according to methods described generally in the Examples herein, or according to methods available to one of ordinary skill in the art.
[00120] In certain exemplary embodiments, compounds of the invention are useful as inhibitors of NaV1.8. .In other embodiments, compounds of the invention are useful as inhibitors . ... of NaVl.8 andCaV2.2.. In still other embodiments, compounds of the invention are useful as inhibitors of CaV2.2.
[00121] It will also be appreciated that certain of the compounds of present invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative thereof. According to the present invention, a pharmaceutically acceptable derivative includes,
• but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a patient in need is capable of providing,
. directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
[00122] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of
-211-

WO 2005/042497 PCT/US2004/036297
humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. A "pharmaceutically acceptable salt" means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. As used herein, the term "inhibitorily active metabolite or residue thereof" means that a metabolite or residue thereof is also an inhibitor of a voltage-gated sodium ion channel.
[00123] Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, .heptanoate, hexanbate, hydroiodide, 2-hydroxy-ethanesulfonate,' lactobionate, lactate,. laurate, lauryl sulfate, malate,. maleate, malonate, methanesulfonate,2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1-4alkyl)4 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed-herein. Water or oil-soluble or dispersable products may be obtained by such quaternization. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such
-212-

WO 2005/042497 PCT/US2004/036297
as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
Pharmaceutically acceptable compositions
[00124] As described above, the pharmaceutically acceptable compositions of the present
invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle,
which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion
or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents,
preservatives, solid binders, lubricants and the like, as suited to the particular dosage form
desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack
Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating
pharmaceutically acceptable compositions and known techniques for the preparation thereof.
Except insofar as any conventional carrier medium is incompatible with the compounds of the
invention, such as by producing any undesirable biological effect or otherwise interacting in a
deleterious manner with any other components) of the pharmaceutically acceptable
composition, its use is contemplated to be within the scope of this invention. Some examples of
materials which can serve as pharmaceutically acceptable carriers include, but are not limited to,
ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum
albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial
glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as
"protamirie sulfate, disodiuin hydrogen phosphate; potassium hydrogen, phosphate, sodium
chloride,, zinc salts, colloidal silica; magnesium trisilicate,polyvinyl pyrrplidone, polyacrylates;
waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose
and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as
sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth;
malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil,
cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a
propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar;
buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-
free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as
well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium
stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and
-213-

WO 2005/042497 PCT/US2004/036297
perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
Uses of Compounds and Pharmaceutically Acceptable Compositions
[00125] In yet another aspect, a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain, arthritis, migrane, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, or incontinence is provided comprising administering an effective amount of a compound, or a pharmaceutically acceptable composition comprising a compound to a subject in need thereof. In certain preferred embodiments, a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain is provided comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof. In certain embodiments of the present invention an "effective amount" of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of acute, chronic, neuropathic, or inflammatory pain, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrythmia, movement disorders, neuroendocrine disorders, ataxia; multiple sclerosis, irritable bowel syndrome, or incontinence. . [00126] The compounds and compositions, according to the method of the present invention,.. may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of acute, chronic, neuropathic, or inflammatory pain, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, or incontinence. The exact amount required • will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be
-214-

WO 2005/042497 PCT/US2004/036297
understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.
[00127] The pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
[00128] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the.active compounds the liquid dqsage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, com, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan,. and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. [00129] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable
-215-

WO 2005/042497 PCT/US2004/036297
solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. [00130] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[00131] In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include p6ly(qrthoesters) and. poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
[00132] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are • solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[00133] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate
-216-

WO 2005/042497 PCT/US2004/036297
and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar—agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[00134] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients. as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
"[00135] ' The active compounds can also be in rnicroencapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as. sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only,
-217-

WO 2005/042497 PCT/US2004/036297
or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. [00136] Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms are prepared by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
[00137] As described generally above, the compounds of the invention are useful as inhibitors of voltage-gated sodium ion channels. In one embodiment, the compounds and compositions of the invention are inhibitors of one or more of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 and thus, without wishing to be bound by any particular theory, the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of NaVl.l, NaV.1.2, NaV1.3, NaV1.4,.NaVl;5, NaVl.6, NaV1.7, NaV1.8, NaVl.9," • pr.CaV2.2 is implicated, in the disease, condition, or disorder,. When activation or hyperactivity . of NaVl.l, NaV1.2, NaVl.3, NaV1.4, NaV1.5, NaV1.6, NaVl'.7, NaV1.8, NaVl.9, or CaV2.2 is implicated in a particular disease, condition, or disorder, the disease, condition, or disorder may also be referred to as a "NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2-mediated disease, condition or disorder". Accordingly, in another aspect, the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaVl._5, NaV1.6, NaV1.7, NaV1.8 or NaV1.9 is implicated in the disease state.
-218-

WO 2005/042497 PCT/US2OO4/036297

[00138J The activity of a compound utilized in this invention as an inhibitor of NaVl.l,
NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaVl.6, NaV1.7, NaVl.8, NaV1.9, or CaV2.2 may be assayed according to methods described generally in the Examples herein. [00139] It will also be appreciated that the compounds and pharmaceutically acceptable compositions of the present invention can be employed in combination therapies, that is, the compounds and pharmaceutically acceptable compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. The particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects). As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as "appropriate for the disease, or condition, being treated". [00140] The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent
[00141] The compounds of this invention or pharmaceutically acceptable compositions thereof may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters. Accordingly, the present invention, in another aspect, includes a composition for coating an implantable device comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. In still another aspect, the present invention includes an implantable device coated with a composition comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. Suitable coatings and the general preparation of coated implantable devices are described in US Patents 6,099,562;
-219-

WO 2005/042497 PCT/US2004/036297
5,88,6026 and 5,304,121. The coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. The coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
[00142] Another aspect of the invention relates to inhibiting NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 activity in a biological sample or a patient, which method comprises administering to the patient, of contacting said biological sample with a compound of formula I or a composition comprising said compound. The term "biological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
[00143] Inhibition of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of sodium ion channels in biological and pathological phenomena; and the comparative evaluation of new sodium ion channel inhibitors.
[00144] In order that the invention described herein may be more fully understood, the following examples are set forth.. It should be understood that these examples are for illustrative purposes only and are not to be. construed as limiting this invention in any fanner
EXAMPLES
SYNTHESIS OF EXEMPLARY COMPOUNDS OF THE INVENTION:
-220-
Example 1:


WO 2005/042497 PCT/US2004/036297
This example teaches the preparation of [2-(l-methyl-lH-benzoimidazol-2-yl)-ethyl]-carbamic acid tert-butyl ester (6). To a solution of beta-alanine (3.5 g, 18.5 mmol) and pyridine (3 mL, 37 mmol) in dichloromethane (20 mL) was added PFP ester (3.2 mL, 18.5 mmol). After stirring at room temperature for 1 hour, 1,2-phenyleneamine 1 (2 g, 18.5 mmol) in dichloromethane (20 mL) was added to the reaction mixture. After stirring overnight, the reaction was quenched with water, extracted with dichloromethane (150 mL*2), dried and removed the solvent. Then the crude mixture was triturated with dichloromethane (20 mL), filtered to give white solid 2 as the desired product (4.8 g) at 90% yield. LC/MS (10-99%) M+l/Z 280.3 retention time 2.03 min.

[00145] Compound 2 (4 g) was dissolved in acetic acid (50 mL) and heated to 65°C for 1 h, then cooled down to room temperature, removed the solvent in vacuo. The residue was taken up with dichloromethane, quenched with sat NaHCO3, extracted with dichloromethane (150 mL) (pH = 10), concentrated to afford 3 as light yellow solid (3.7 g) at 100% yield. LC/MS (10-99%) M+l/Z 262.2 retention time 2.30 min.

[00146] Compound 3 (3 g) was dissolved in 3 N HCl/EtOAC (50 mL/25 mL) and stirred at
room temperature overnight. The solvent was in vacuo and dried in high vacuum to give
compound 4 as pink solid (2.4 g) at greater than 95% yield. LC/MS (10-99%) M+l/Z 162.4
retention time 0.62 min. ... ...

-221-

WO 2005/042497 PCT/US2004/036297
[00147] To a solution of benzimidazole ethylene amine dihydrochloride (100 mg, 0.43 mmol), 3,4-dimethylphenoxyacetic acid (77 mg, 0.43 mmol), and BOP reagent (190 mg, 0.43 mmol) in acetonitrile (5 mL) was added triethylamine (0.23 mL, 1.72 mmol). After stirring at room temperature overnight, the solvent was removed under vacuum. The residue was taken up with water and saturated sodium bicarbonate (20 mL), extracted with dichloromethane (30 mL x 2), dried and removed the solvent. The crude mixture was purified by using Gilson HPLC to give white solid 5 as a TFA salt (170 mg) at 93 %yield. MUX LC/MS (10-99%) M+l/Z 324.163 retention time 2.62 min; 1H NMR (DMSO) d 2.12 (s, 3H), d 2.15 (s, 3H), d 2.99 (t, 2H, J = 5.88 Hz), d 3.59 (m, 2H), d 4.40 (s, 2H), d 6.64 (dd, 1H, J=2 Hz, 6.5 Hz), d 6.75 (d, 1H,J= 1.8 Hz), d 6.98 (d,1H, /= 6.6 Hz), d 7.12 (m, 2H), 7.40 (d, 1H, J= 5.76 Hz), 7.53 (m, 1H), 8.30 (t, 1H, J = 4.56 Hz), 12.24 (s, 1H); 13C NMR (DMSO) d 18.4, d 19.57, d 28.58, d 36.74, d 67.07, d 110.8, d 111.58, d 116.13, d 118.12, d 120.86, d 121.52, d 128.70, d 130.12, d 134.21, d 137.25, d143.24, d152.74, d155.73,d 167.85.

[00148] Boc-protected benzimidazole ethyl amine 3 (400 mg, 1.53 mmol) was dissolved in THF (50 mL) and cooled to 0°C under nitrogen, followed by dropwise addition of LiHMDS (535 . mg, 3.37 mmol) in THF(10 mL) via syringe. The mixture was warmed to room temperature and . . stirred for 20 min. Methyl iodide (0.1 .mL, .1.68.mmo1);.was.".added dropwise to the reaction mixture. After stirring for 5 h at room temperature, the reaction was quenched with water (20 mL) and extracted with EtOAc (30 mL x 2), dried, concentrated and purified by ISCO flash chromatography.

This example teaches the preparation of [2-(lH-benzoimidazol-2-yl)-ethyl]-carbamic acid 3,4-dimethyl-benzyl ester. To a solution of 3,4-dimethylbenzyl alcohol (1.5 g, 11.0 mmol) in
-222-

WO 2005/042497 PCT/US2004/036297
toluene (20 mL) was added phosgene (13 mL, 24.3 mmol, 20% in toluene). After stirring at room temperature overnight, excess phosgene and toluene was removed in vacuo, and dried under high vacuum for 2 h. providing 3,4-dimethylbenzylchloroformate (1.8 g) as an oil at 80 % yield. (reference: Nagele, E.; Schelhaas, M.; Kuder, N.; Waldmann, H. J. Am. Chem. Soc. 1998, 120, 6889)

This example teaches the preparation of l-[2-(1H-benzoimidazol-2-yl)-ethyl]-3-(3,4-dichloro-benzyl)-urea. To a solution of benzimidazole ethyl amine dihydrochloride (50 mg, 0.21 mmol) in pyridine (1.5 mL) was added 3,4-dichlorobenzylisocyanate (43 µL, 0.21 mmol). After stirring overnight at room temperature, the crude mixture was purified by Gilson HPLC to afford white solid (50 mg) as a TFA salt at 92% yield. LC/MS (10-99%) M+l/Z 324.2 retention time 2.97 min.

This example teaches the preparation of N-[2-(lH-Benzoimidazol-2-yl)-ethyl]-3,4-dichloro-
benzenesulfonamide. To a solution of benzimidazole ethyl amine dihydrochloride (50 mg, 0.21
mmol) in pyridine (1.5 mL) was added 3,4-dichlorobenzyisocyanate (58 µL, 0.21 mmol). After
stirring overnight at room temperature, the crude mixture was purified by Gilson HPLC to afford
white solid (55 mg) as TFA salt at 92% yield. . . • •

-223.-

WO 2005/042497 PCT/US2004/036297
This example teaches the preparation of 2-(2,6-Difluoro-phenyl)-7-methyl-l#-benzoimidazole according to the following procedure. A solution of 3-methyl-benzene-l,2-diamine (100 mg, 0.82 mmol) and 2,6-difluorobenzaldehyde in EtOH (2 mL) was heated for 5 min at 180°C in a microwave synthesizer. The EtOH was removed, the residue was dissolved in DMSO (1 mL), and was purified on a Gilson HPLC to afford 2-(2,6-difluoro-phenyl)-7-methyl-lH-benzoimidazole as TFA salt (200 mg) at 100% yield. MUX LC/MS (10-99%) M+l/Z 245.061 retention time 2.1 min.

-224-
[00149] Other compounds of Formula I have been prepared by methods substantially similar to those described above. The characterization data for these compounds is summarized in Table 3 below. The compound numbers correspond to the compound numbers listed in Table 2.

WO 2005/042497 PCT/US2004/036297

Micromass MUX LCT 4 channel LC/MS, Waters 60F pump, Gilson 215 4 probe autosampler, Gilson 849 injection module, 1.5 mL/min/coIumn flow rate, 10-99% CH3CN (0.035 % TFA) / H2O (0.05 % TFA) gradient, Phenomenex Luna 5u C18 columns (50 x 4.60 mm), Waters MUX UV-2488 UV detector, Cedex 75 ELSD detectors.
ASSAYS FOR DETECTING AND MEASURING NaV INHIBITION PROPERTIES OF COMPOUNDS
[00150] A) Optical methods for assaying NaV inhibition properties of compounds:
-225-

WO 2005/042497 PCT/US2004/036297
[00151] Compounds of the invention are useful as antagonists of voltage-gated sodium ion channels. Antagonist properties of test compounds were assessed as follows. Cells expressing the NaV of interest were placed intomicrotiter plates. After an incubation period, the cells were stained with fluorescent dyes sensitive to the transmembrane potential. The test compounds were added to the microtiter plate. The cells were stimulated with either a chemical or electrical means to evoke a NaV dependent membrane potential change from unblocked channels, which was detected and measured with trans-membrane potential-sensitive dyes. Antagonists were detected as a decreased membrane potential response to the stimulus. The optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells" Biophvs J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer" Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VDPR®) (See, Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets" Drug Discov Today 4(9): 431-439).
[00152] B) VDPR® optical membrane potential assay method with chemical stimulation Cell Handling and Dye Loading
[00153] 24 hours before the assay on VIPR, CHO cells endogenously expressing a NaV1.2 type voltage-gated NaV are seeded in 96-well poly-lysine coated plates at 60,000 cells per well: Other subtypes are performed in an analogous mode in a cell line expressing the NaV of interest
1) On the day of the assay, medium is aspirated and cells are washed twice with 225 µL of Bath
Solution #2 (BS#2).
2) A 15 uM CC2-DMPE solution is prepared by mixing 5 mM coumarin stock solution with
10% Pluronie 127 1:1 and then dissolving the mix in the appropriate volume of BS#2.
3) After bath solution is removed from the 96-well plates, the cells are loaded with 80 µL of the
CC2-DMPE solution. Plates are incubated in the dark for 30 minutes at room temperature.
4) While the cells are being stained with coumarin, a 15 µL oxonol solution in BS#2 is
prepared. In addition to DiSBAC2(3), this solution should contain 0.75 mM ABSC1 and 30
µL veratridine (prepared from 10 mM EtOH stock, Sigma #V-5754).
-226-

WO 2005/042497 PCT/US2004/036297
5) After 30 minutes, CC2-DMPE is removed and the cells are washed twice with 225 µL of
BS#2. As before, the residual volume should be 40 µL.
6) Upon removing the bath, the cells are loaded with 80 µL of the DiSBAC2(3) solution, after
which test compound, dissolved in DMSO, is added to achieve the desired test concentration
to each well from the drug addition plate and mixed thoroughly. The volume in the well
should be roughly 121 µL. The cells are then incubated for 20-30 minutes.
7) Once the incubation is complete, the cells are ready to be assayed on VIPR® with a sodium
addback protocol. 120 µL of Bath solution #1 is added to stimulate the NaV dependent
depolarization. 200 µL tetracaine was used as an antagonist positive control for block of the
NaV channel.
Analysis of VIPR® Data:
[00154] Data are analyzed and reported as normalized ratios of background-subtracted emission intensities measured in the 460 run and 580 nm channels. Background intensities are then subtracted from each assay channel. Background intensities are obtained by measuring the emission intensities during the same time periods from identically treated assay wells in which there are no cells. The response as a function of time is then reported as the ratios obtained using, the following formula:
. (intensity-460 nm - background 460 nm) (intensity 580 nm - background 580 nm)
[00155] The data is further reduced by calculating the initial (R1) and final (Rf) ratios. These are the average ratio values during part or all of the pre-stimulation period, and during sample points during the stimulation period. The response to the stimulus 2? = Rf/R1 is then palculated. For the Na+ addback analysis time windows, baseline is 2-7 sec and final response is sampled at 15-24 sec.
[00156] Control responses are obtained by performing assays in the presence of a compound with the desired properties (positive control), such as tetracaine, and in the absence of
-227-

WO 2005/042497 PCT/US2004/036297
pharmacological agents (negative control). Responses to the negative (N) and positive (P) controls are calculated as above. The compound antagonist activity A is defined as:
where R is the ratio response of the test compound
Solutions [mM]
Bath Solution #1: NaCl 160, KCl4.5, CaCl2 2, MgCl2 1, HEPES 10, pH 7.4 with NaOH
Bath Solution #2 TMA-Cl160, CaCl2 0.1, MgCl2 1, HEPES 10, pH 7.4 with KOH (final K
concentration - 5 mM)
CC2-DMPE: prepared as a 5 mM stock solution in DMSO and stored at -20°C
DiSB AC2(3): prepared as a 12 mM stock in DMSO and stored at -20°C
ABSC1: prepared as a 200 mM stock in distilled H2O and stored at room
temperature
Cell Culture
[00157] CHO cells are grown in DMEM (Dulbecco's Modified Eagle Medium; GibcoBRL
#10569-010) supplemented with 10% FBS (Fetal Bovine-Serum, qualified; GibcpBRL #16140-
071) and. 1%. Pen-Strep (Penicillin-Streptomycin;GibcoBRL #15140-122).Cells are grown in
vented cap flasks, in 90% humidity and 10% CO2, to 100% confluence. They are usually split by
trypsinization 1:10 or 1:20, depending on scheduling needs, and grown for 2-3 days before the
next split.
[00158] C) VTPR® optical membrane potential assay method with electrical stimulation
[00159] The following is an example of how NaV1.3 inhibition activity is measured using the
optical membrane potential method#2. Other subtypes are performed in an analogous mode in a
cell line expressing the NaV of interest.
[00160] HEK293 cells stably expressing NaV1.3 are plated into 96-well microtiter plates.
After an appropriate incubation period, the cells are stained with the voltage sensitive dyes CC2-
DMPE/DiSBAC2(3) as follows.
-228-

WO 2005/042497 PCT/US2004/036297
Reagents:
100 mg/mL Pluronic F-127 (Sigma #P2443), in dry DMSO
10 mM DiSBAC2(3) (Aurora #00-100-010) in dry DMSO
10mMCC2-DMPE (Aurora #00-100-008) in dry DMSO
200mMABSCl in H20
Hank's Balanced Salt Solution (Hyclone #SH30268.02) supplemented with 10 mM HEPES
(Gibco #15630-080)
Loading protocol:
[00161] 2X CC2-DMPE = 20 µM CC2-DMPE: 10 mM CC2-DMPE is vortexed with an
equivalent volume of 10% pluronic, followed by vortexing in required amount of HBSS
containing 10 mM HEPES. Each cell plate will require 5 mL of 2X CC2-DMPE. 50 µL of 2X
CC2-DMPE is to wells containing washed cells, resulting in a 10 µM final staining
concentration. The cells are stained for 30 minutes in the dark at RT.
[00162] 2X DISBAC2(3) with ABSC1 = 6µM DISBAC2(3) and 1 mM ABSC1: The
required amount of 10 mM DISBAC2(3) is added to a 50 ml conical tube and mixed with 1 µL
10% pluronic for each mL of solution to be made and vortexed together. Then HBSS/HEPES
is added to make up 2X solution. Finally, the ABSC1 is added .
[00163] The 2XDiSBAC2(3) solution can be used to solyate compoimd plates. Note that
compound plates are made at 2X drug concentration. Wash stained plate again, leaving residual
volume of 50 µL. Add 50 uL/wellof the 2X DiSBAC2(3) w/ ABSC1. Stain for 30 minutes in
the dark at RT.
[00164] The electrical stimulation instrument and methods of use are described in ION
Channel Assay Methods PCT/US01/21652, herein incorporated by reference. The instrument
comprises a microtiter plate handler, an optical system for exciting the coumarin dye while
simultaneously recording the coumarin and oxonol emissions, a waveform generator, a current-
or voltage-controlled amplifier, and a device for inserting electrodes in well. Under integrated
computer control, this instrument passes user-programmed electrical stimulus protocols to cells
within the wells of the microtiter plate.
Reagents
-229-

WO 2005/042497 PCT/US2004/036297
[OO165] Assay buffer #1
140 mM NaCl, 4.5 mM KC1, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 10 mM glucose, pH
7.40, 330 mOsm
Pluronic stock (1000X): 100 mg/mL pluronic 127 in dry DMSO Oxonol stock (3333X): 10 mM DiSBAC2(3) in dry DMSO Coumarin stock (1000X): 10 mM CC2-DMPE in dry DMSO ABSC1 stock (400X): 200 mM ABSC1 in water
Assay Protocol
1. Insert or use electrodes into each well to be assayed.
2. Use the current-controlled amplifier to deliver stimulation wave pulses for 3 s. Two
seconds of pre-stimulus recording are performed to obtain the un-stimulated intensities.
Five seconds of post-stimulation recording are performed to examine the relaxation to the
resting state.
Data Analysis
[00166] Data are analyzed and reported as normalized ratios of background-subtracted emission intensities measured in the 460 nm and 580 nm channels. Background intensities are then subtracted from each assay channel. Background intensities are obtained by measuring the ¦ emission intensities during the same time periods from dentically treated assay wells in which' there are no cells. The response as a function of time is then reported as the ratios obtained using the following formula:

[00167] The data is further reduced by calculating the initial (R1 and final (Rf) ratios. These are the average ratio values during part or all of the pre-stimulation period, and during sample points during the stimulation period. The response to the stimulus R = Rf/R1 is then calculated.
-230-

WO 2005/042497 PCT/US2004/036297
[00168] Control responses are obtained by performing assays in the presence of a compound with the desired properties (positive control), such as tetracaine, and in the absence of pharmacological agents (negative control). Responses to the negative (N) and positive (P) controls are calculated as above. The compound antagonist activity A is defined as:
where R is the ratio response of the test compound.
[00169] ELECTROPHYSIOLOGY ASSAYS FOR NaV ACTIVITY AND INHBITION OF
TEST COMPOUNDS
[00170] Patch clamp electrophysiology was used to assess the efficacy and selectivity of
sodium channel blockers in dorsal root ganglion neurons. Rat neurons were isolated from the
dorsal root ganglions and maintained in culture for 2 to 10 days in the presence of NGF (50
ng/ml) (culture media consisted of NeurobasalA supplemented with B27, glutamine and
antibiotics). Small diameter neurons (nociceptors, 8-12 urn in diameter) have been visually
identified and probed with fine tip glass electrodes connected to an amplifier (Axon
Instruments). The "voltage clamp" mode has been used to assess the compound's IC50 holding
the cells at - 60 mV. In addition, the "current clamp" mode has been employed to test the
efficacy of the compounds in blocking action potential generation in response to current
injections. The results of these experiments have contributed to the definition of the efficacy
profile of the compounds.
[00171] VOLTAGE-CLAMP assay in DRG neurons
[00172] TTX-resistant sodium curiehts were recorded from DRG somata using the whole-cell
variation of the patch clamp technique. Recordings were made at room temperature (-22° C) with thick walled borosilicate glass electrodes (WPI; resistance 3-4 MO) using an Axopatch 200B amplifier (Axon Instruments). After establishing the whole-cell configuration, •approximately 15 minutes were allowed for the pipette solution to equilibrate within the cell before beginning recording. Currents were lowpass filtered between 2-5 kHz and digitally sampled at 10 kHz. Series resistance was compensated 60-70% and was monitored continuously throughout the experiment. The liquid junction potential (-7 mV) between the intracellular pipette solution and the external recording solution was not accounted for in the data analysis.
¦ 231-

WO 2005/042497 PCT/US2004/036297
Test solutions were applied to the cells with a gravity driven fast perfusion system (SF-77;
Warner Instruments).
[00173] Dose-response relationships were determined in voltage clamp mode by repeatedly
depolarizing the cell from the experiment specific holding potential to a test potential of +10mV
once every 60 seconds. Blocking effects were allowed to plateau before proceeding to the next
test concentration.
Solutions
[00174] Intracellular solution (in mM): Cs-F (130), NaCl (10), MgCl2 (1), EGTA (1.5),
CaCl2 (0.1); HEPES (10), glucose (2), pH = 7.42,290 mOsm.
[00175] Extracellular solution (in mM): NaCl (138), CaCl2 (1.26), KCI (5.33), KH2PO4
(0.44), MgCl2 (0.5), MgSO4 (0.41), NaHCO3 (4), Na2HPO4 (0.3), glucose (5.6), HEPES (10),
CdC12 (0.4 ), NiC12 (0.1), TTX (0.25 x 10-3).
[00176] CURRENT-CLAMP assay for NaV channel inhibition activity of compounds [00177] Cells were current-clamped in whole-cell configuration with a Multiplamp 700A amplifier (Axon Inst). Borosilicate pipettes (4-5 MOhm) were filled with (in mM):150 K-gluconate, 10 NaCl, 0.1 EGTA, 10 Hepes, 2 MgCl2, (buffered to pH 7.34 with KOH). Cells were bathed in (in mM): 140 NaCl, 3 KCI, 1 MgCl , 1 CaCl , and 10 Hepes). Pipette potential was zeroed before seal formation; liquid, junction potentials were not corrected during acquisition. Recordings were made at room temperature.
[00178] ASSAYS FOR DETECTING AND MEASURING CaV INHIBITION PROPERTIES OF COMPOUNDS
A) Optical methods for assaying CaV inhibition properties of compounds: [00179] Compounds of the invention are useful as antagonists of voltage-gated calcium ion channels. Antagonist properties of test compounds were assessed as follows. Cells expressing the CaV of interest were placed into microtiter plates. After an incubation period, the cells were stained with fluorescent dyes sensitive to the transmembrane potential. The test compounds were added to the microtiter plate. The cells were stimulated with electrical means to evoke a CaV dependent membrane potential change from unblocked channels, which was detected and measured with trans-membrane potential-sensitive dyes. Antagonists were detected as a
-232-

WO 2005/042497 PCT/US2004/036297
decreased membrane potential response to the stimulus. The optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells" Biophvs J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer" Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VTPR®) (See, Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets" Drug Discov Today 4(9): 431-439).
[00180] VIPR® optical membrane potential assay method with electrical stimulation [00181] The following is an example of how CaV2.2 inhibition activity is measured using the optical membrane potential method. Other subtypes are performed in an analogous mode in a cell line expressing the CaV of interest.
[00182] HEK293 cells stably expressing CaV2.2 are plated into 96-well microtiter plates. After an appropriate incubation period, the cells are stained with the voltage sensitive dyes CC2-DMPE/DiSBAC2(3) as follows.
Reagents:
100 mg/mL Pluronic F-127 (Sigma #P2443), in dry DMSO 10 mM DiSBAC6(3) (Aurora #00-100-010) in dry DMSO 10'mM,CC2-DMP.E (Aurora#00-100^6.08) in dry DMSO 200 mM Acid Yellow 17 (Aurora #VABSC) in H20 370mM Barium Chloride (Sigma Cat# B6394) in H20
BathX
l60mM NaCl (Sigma Cat# S-9888) 4.5mM KC1 (Sigma Cat# P-5405) lmM MgC12 (Fluka Cat# 63064) l0mM HEPES (Sigma Cat# H-4034) pH 7.4 using NaOH
-233-

WO 2005/042497 PCT/US2004/036297
Loading rotocol:
[00183] 2X CC2-DMPE = 20 µM CC2-DMPE: 10 mM CC2-DMPE is vortexed with an equivalent volume of 10% pluronic, followed by vortexing in required amount of HBSS containing 10 mM HEPES. Each cell plate will require 5 mL of 2X CC2-DMPE. 50 µL of 2X CC2-DMPE is added to wells containing washed cells, resulting in a 10 µM. final staining concentration. The cells are stained for 30 minutes in the dark at RT.
[00184] 2X CC2DMPE & DISBAC6(3) = 8 µM CC2DMPE & 2. 5 µM DISBAC6(3): Vortex together both dyes with an equivalent volume of 10% pluronic (in DMSO). Vortex in required amount of Bath X with beta-cyclodextrin. Each 96well cell plate will require 5 ml of 2XCC2DMPE. Wash plate with ELx405 with Bath X, leaving a residual volume of 50 µL/well. Add 50 µL of 2XCC2DMPE & DISBAC6(3) to each well. Stain for 30 minutes in the dark at RT.
[00185] 1. 5X AY17 = 750 µM AY17 with 15mM BaCl2: Add Acid Yellow 17 to vessel containing Bath X. Mix well. Allow solution to sit for 10 minutes. Slowly mix in 370mM BaCl2. This solution can be used to solvate compound plates. Note that compound plates are made at 1.5X drug concentration and not the usual 2X. Wash CC2 stained plate, again, leaving residual volume of 50 µL. Add 100 uL/well of the AY17 solution. Stain forl5 minutes in the dark at RT. Run plate on the optical reader.
[00186] The electrical stimulation instrument and methods of use are described in ION Channel Assay Methods PCT/US01/21652, herein incorporated by reference. The. instrument comprises a. microtitef, plate, handler,, an optical system for exciting the coumarin dye while. simultaneously recording the coumarin and oxonol emissions, a waveform generator, a current-or voltage-controlled amplifier, and a device for inserting electrodes in well. Under integrated computer control, this instrument passes user-programmed electrical stimulus protocols to cells within the wells of the microtiter plate. Assay Protocol
[00187] Insert or use electrodes into each well to be assayed.
[00188] Use the current-controlled amplifier to deliver stimulation waye pulses for 3-5 s. Two seconds of pre-stimulus recording are performed to obtain the un-stimulated intensities. Five seconds of post-stimulation recording are performed to examine the relaxation to the resting state.
-234-

WO 2005/042497 PCT/US2004/036297
Data Analysis
[00189] Data are analyzed and reported as normalized ratios of background-subtracted emission intensities measured in the 460 run and 580 nm channels. Background intensities are then subtracted from each assay channel. Background intensities are obtained by measuring the emission intensities during the same time periods from identically treated assay wells in which there are no cells. The response as a function of time is then reported as the ratios obtained using the following formula:

[00190] The data is further reduced by calculating the initial (R1) and final (Rf) ratios. These are the average ratio values during part or all of the pre-stimulation period, and during sample points during the stimulation period. The response to the stimulus R = Rf/Ri is then calculated. [00191] Control responses are obtained by performing assays in the presence of a compound with the desired properties (positive control), such as mibefradil, and in the absence of pharmacological agents (negative control). Responses to the negative (N) and positive (P) controls are calculated as above. The compound antagonist activity A is defined as:
where R is the ratio response of the test compound.
[00192] ELECTROPHYSIOLOGY ASSAYS FOR CaV ACTIVITY AND INHBITION OF
TEST COMPOUNDS
[00193] Patch clamp electrophysiology was used to assess the efficacy of calcium channel
blockers expressed in HEK293 cells. HEK293 cells expressing CaV2.2 have been visually
identified and.probed with fine tip glass electrodes connected, to an amplifier (Axon.
Instruments). The "voltage clamp" mode has been used to assess the compound's IC50 holding
the cells at - 100 mV. The results of these experiments have contributed to the definition of the
efficacy profile of the compounds.
VOLTAGE-CLAMP assay in HEK293 cells expressing CaV2.2
-235-

WO 2005/042497 PCT/US2004/036297
[00194] CaV2.2 calcium currents were recorded from HEK293 cells using the whole-cell variation of the patch clamp technique. Recordings were made at room temperature (-22° C) with thick walled borosilicate glass electrodes (WPI; resistance 3-4 MO) using an Axopatch 200B amplifier (Axon Instruments). After establishing the whole-cell configuration, approximately 15 minutes were allowed for the pipette solution to equilibrate within the cell before beginning recording. Currents were lowpass filtered between 2-5 kHz and digitally sampled at 10 kHz. Series resistance was compensated 60-70% and was monitored continuously throughout the experiment. The liquid junction potential (-7 mV) between the intracellular pipette solution and the external recording solution was not accounted for in the data analysis. Test solutions were applied to the cells with a gravity driven fast perfusion system (SF-77; Warner Instruments).
[00195] Dose-response relationships were determined in voltage clamp mode by repeatedly depolarizing the cell from the experiment specific holding potential to a test potential of +20mV for 50ms at frequencies of 0.1,1, 5,10,15, and 20 Hz. Blocking effects were allowed to plateau before proceeding to the next test concentration. [00196] Solutions
[00197] Intracellular solution (in mM): Cs-F (130), NaCl (10), MgCl2 (1), EGTA (1.5), CaCl2 (0.1), HEPES (10), glucose (2), pH = 7.42, 290 mOsm.
[00198] Extracellular solution (in mM): NaCl (138), BaCl2 (10), KC1 (5.33), KH2PO4.(0.44), MgCl2(0.5),MgSp4(0.41),.NaHCQ3 (4), Na2HPO4 (6.3), glucose (5.6), HEPES. (10) [00199] Following these procedures'; representative compounds of the'present invention were' found to possess desired N-type calcium channel modulation activity.
-236-

WO 2005/042497 PCT/US2004/036297
[00200] Compounds of the invention as shown in Table 2 were found modulate voltage-gated sodium channels at 25.0 µM or less.
[00201] In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
-237-

WO 2005/042497 PCT/US2004/036297
We claim
1. A compound of Formula I:

or a phannaceutically acceptable salt thereof, wherein:
r is 0 to 4;
Z is O,N or CH;
Y and W are independently selected from hydrogen, Formula Ia:
wherein:
Ais-T-NH-; wherein:
T is a bond or a C1-6 straight or branched aliphatic chain wherein a methylene unit
of T is optionally replaced by a C3-6 cycloaliphatic group; U is-CH2-or-CH2-CH2-; ... X is N-C1-4allcyl, NH, O, S, S(O), or SO2; and each occurrence of RC is independently M-Rx; wherein:
M is a bond or is a C1-6 alkylidene chain wherein up to two non-adjacent methylene units of M are optionally replaced by C(O), CO2, C(O)C(O), C(O)NR, OC(O)NR, NRNR, NRNRC(O), NRC(O),
- 238 -
AMENDED PAGE

WO 2005/042497 PCT/US2004/036297
NRCO2, NRC(O)NR, S(O), SO2, NRSO2, SO2NR, NRSO2NR, O, S, or NR, and Rx is R, halogen, NO2, or CN; wherein;
each occurrence of R' is independently selected from hydrogen or an .
optionally substituted group selected from C1-8 aliphatic, C6-10 aryl,
a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 3-10 ring atoms, or R and R' taken together with the atom(s) to which they are bound, or two occurrences of R' taken together with the atom(s) to which they are bound, form a 5-8 membered cycloalkyl, heterocyclyl, aryl, or heteroaryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
V is a bond, -C(O)-, or -S (O)2-; Q is a bond or a C1-4 alkylidene chain wherein up to two non-adjacent methylene units c
Q are optionally replaced by -O-, -NH-, or -S-; m is 0 or 1;
Ring E is C6-10 aryl, a 5-10 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 3-10 membered heterocyclyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and s is0 to 5; or Formula Ib:
wherein: D is -C1-6allcyl- or a bond; and t is 0 to 5;
each occurrence of R is independently selected from hydrogen or an optionally substituted C1-6 aliphatic group; and
-239-
AMENDED PAGE

WO 2005/042497 PCT/US2004/036297
each ocurence of RA, RB and RD are independently selected from R1, R2, R3, R4, or R5, wherein:
Rl-is oxo, R6 or (C1-4aliphatic)n-J, wherein: n is 0 or l; J is halo, CN, NO2, CF3, OCF3, OH, SR6, S(O)R6, SO2R6, NH2, NHR6, N(R6)2,
NR6R8, C(O)OH, C(O)OR6 or OR6; or: two Rl on adjacent ring atoms, taken together, form 1,2-methylenedioxy or 1,2-

ethylenedioxy;
R2 is C1-6aliphatic, optionally substituted with up to two substituents independently selected from R1, R4, or R5;
R3 is C3-8cycloaliphatic, C6-10 aryl, a 5-10 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 3-10 membered heterocyclyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R3 is optionally substituted with up to three substituents independently selected from R1, R2, R4 or R5;
R4 is OR5, OR6, OC(O)R6, OC(O)R5, OC(O)0R6, OC(O)OR5, OC(O)N(R6)2 OC(O)NCR5)2, OC(O)N(R6R5), SR6, SR5, S(O)R6, S(O)R5, SO2R6, SO2R5, SO2NCR6)2,SO2N(R'5)2, SO2NR5R6', SO3R6,SO3R5, C(O)R5, C(0)6R5,'
C(O)N(OR5)R6, C(O)N(OR6)R5, C(O)N(OR5)R5, C(NOR6)R6, C(NQR6)R5, C(NOR5)R6, CCNOR5)R5, N(R6)2, N(R5)2, N(R5R6), NR5c(O)R5, NR6C(O)R6,
NR6C(O)R5, NR6C(O)OR6, NR5C(O)OR6, NR6C(O)OR5, NR5C(O)OR5,
NR6C(O)N(R6)2, NR6C(O)NR5R6','NR6C(O)NCR5)2, NH5C(O)N(R6)2
NR5C(O)NR5R6, NR5C(O)N(R5)2, NR6SO2R6, NR6SO2R5, NR5SO2R5,
NR6SO2NCR6)2, NR6SO2NR5R6, NR6SO2N(R5)2, NR5SO2NR5R6 NR5SO2N(R5)2, N(OR6)R6, N(OR6)R5, N(OR5)R5, orN(OR5)R6;
-240-
AMENDED PAGE

WO 2005/042497 PCT/US2004/036297
K5 is a C3-8cycloaliphatic, C6-10 aryl, a 5-10 membered heteroaryl ring having 1-4 hetexoatoms independently selected from nitrogen, oxygen, or sulfur, ox a 3-10 membered heterocyclyl ring having 1-4 heteroato'ms independently selected from nitrogen, oxygen, or sulfur, wherein R5 is optionally substituted with up to three R1 substituents;
R6 is R optionally substituted with R7, wherein:
R7 is a C3-8cycloaliphatic, C6-10 aryl, a 5-10 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 3-10 membered heterocyclyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R7 is optionally substituted with up to two substituents independently selected from R, 1,2-methylenedioxy, 1,2-ethylenedioxy, or (CH2)n-G, wherein G is selected from halo, CN, NO2, CF3,
OCF3, OH, S-aliphatic, S(O)-aliphatic, SO2-aliphatic, NH2, N-aliphatic, N(aliphatic)2, N(aHphatic)R8, COOH, C(O)O(-aliphatic, or O-aliphatic; and
R8 is an ammo protecting group;
provided that only one of Y and W is formula Ia or Ib and the other of Y and W is hydrogen; and wherein:
(a) when Zis N, Y is hydrogen W is formula Ia, A is-and V and Q are each a
bond, then:
(i) when r is 1 and RA is methyl in the C-5 or C-6 position of the benzimidazole ring, then E is not:
unsubstitued phenyl;,
phenyl substituted in the ortho position with methyl, OMe, or OEt; or phenyl substituted in the para position with OMe or methyl; and (ii) when r is 0, then E is not: unsubstituted phenyl; unsubstituted naphthyl;
-241-
AMENDED PAGE.

WO 2005/042497 PCT/US2004/036297
phertyl substituted in the para position with OEt, Br, OH, or OMe; phenyl substituted in the meta position with chloro; or phenyl substituted in the ortho position with methyl;
(b) when Z is N, Y is hydrogen, W is formula Ia, Q is -NHCH2-, r is 0, and V is C(O), then:
(i) when A is -CH2CH2NH-, then E is not
(ii) when A is -CH3NH-, then E is not
(c) when Z is C, W is hydrogen, Y is formula Ia, r is 0, A.is -CH2CH2NH-, V is C(O), Q is
-CH2O- and E is phenyl, then:
(i) s is not 0;
(ii) when s is 1, RB is not:
unsubstituted phenyl, chloro, OMe, methyl, bromo,
in the para position; cyano or OMe in the ortho position or • methyl in the meta position; •
(in) when s is 2, RB is not dichloro in the ortho/para positions; and (iv) when s is 3, RB is not 2,3,4-trimcthyoxy or 2,4,5-trichloro; and wherein:
a) when Z is N, W is Formula Ia, A is -CH2CH2NH-, V is -C(O)-, Q is -CH2O-, and Ring E is
phenyl, then RA is not -Cl, -Br, C1-4alkyl, methoxy, or nitro, either singly or in combination;
b) when Z is N, W is Formula Ia, A is -CH2CH2NH-, V is -C(O)-, Q is a bond, and Ring E is
phenyl, then RA is not -Cl, -Br, C1-4alkyl, methoxy, or nitro, either singly or in combination;
c) when Z is N, "W is Formula Ia, A is -CH2CH2CH2NH-, V is -C(O)-, Q is a bond, and Ring E
is phenyl, then RA is not 4-amino, or 4-methoxycarbonyl;
-242-
AMENDED PAGE,

WO 2005/042497 _ PCT/US2004/036297
d) when Z is N, W is Formula Ia, A is -CH2CH2CH2NH-, V is -C(O)-, and Q is a bond, then
King E is not -2(2,3-dihydro-benzo[l,4]dioxiiie);
e) when Z is N, W is Formula Ia, A is -CH2CH2CH2NH-, V is -C(O), and Q is a -CH2O-, then
Ring E is not ~6(4-dimemyl-2H-chrbmen-2-one);
f) when Z is N, W is Formula la, A is -CH2CH2NH-, V is -C(O)-, and Q is a -CH2CH2O-, then
RmgE is not unsubstituted phenyl;
g) when Z is N, W is Formula la, A is -CH2CH2NH-, V is -C(O)-, and Q is a bond, then Ring E
is not unsubstituted thienyl; ;
h) when Z is N, W is Formula la, A is -CH2CH2NH-, V is ~C(O)-, and Q is a -CH2O-, and Ring
E is phenyl, then RA is not phenyl at the 4 position; i) when Z is N, W is Formula la, A is -CH2CH2NH-, V is -C(O)-, and Q is -CH2CH2-, then
Ring E is not 2-isoindoline-l,3-dione; j) when Z is N, W is Formula la, A is -CH2CH2NH-, V is -C(O)-, and Q is -CH2CH2O-, and
Ring E is phenyl, then RA is not phenyl at the 4 position; and k) when Z is N, W is Formula la, A is -CH2CH2NH-, V is ~C(O)-, and Q is a bond, then Ring E
is not unsubstituted adamantyl.
1) when Z is N, W is Formula Ia, A is -CH2CH2NH-, V is -C(O)-, Q is -CH2CH2O-, and Ring E is phenyl, then RB is not-Cl, -Br, C1-4alkyl, methoxy, unsubstituted phenyl, -C(CH3)2phenyl, or nitro, either singly or in combination;
m) when Z is N, W is Formula la, A is -CH2CH2NH-, V is -C(O)r, Q is -CH=CH2-, and Ring E is phenyl, then RB is not -Cl in the ortho position; and
n) wnen Z is N, W is Formula la, A is -CH2CH2NH-, V is ~SO2-, Q is a bond, and Ring E is phenyl, then RB is not chloro.
2. The compound according to claim 1, wherein:
Ais T-NR6-, wherein T is; a C1-6 straight or branched aliphatic chain
Q is -CH2CH2O-, -CH2O-, -OCH2-, -OCH2CH2-, -CH(CH3)O-, -NHCH2-, -C(CH3)2O-, or
-CH2S-; and Ring E is selected from phenyl, naphthyl, pyridyl, thienyl, furanyl, quinolinyl, or benzofuranyl.
3. The compound according to claim 1, wherein said compound is of formula Ha:
-243-
AMENDED PAGE

WO 2005/042497 PCT/US2004/036297

or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 3, wherein:
Q is -CH2CH2O-, -CH2O-, -OCH2-, -OCH2CH2-, -CH(CH3)O-,-NHCH2-, -C(CH3)2O-, or
-CH2S-;
A is -CH2CH2N(CH3)-, -CH3CH2NH-, -CH2NH-, or -CH2GH(CH3)NH-; and each RB is independently OR6, N(R6)2 NR6C(O)R6, halo, R6, C(O)R6, orNO2.
5. The compound according to claim 3, wherein A is
6. The compound according to claim 3, wherein A is
7. The compound according to claim 3, wherein A is -T-NH- wherein T is a C1-6 straight or
branched aliphatic chain and wherein a methylene unit of T is replaced by a C3-6 cycloaliphatic
group.
¦ 8. The compound according to claim 1, wherein said compound is of formula HI:
-244-
AMENDED PAGE

WO 2005/042497 PCT/US2004/036297
or a phannaceutically acceptable salt thereof.
9. The compound according to claim 8, wherein:
Q is -CH2CH2O-, -CH2O-, -OCH2-, -OCH2CH2-, -CH(CH3)O-, -NHCH2-, -C(CH3)2O-, or
-CH2S-;
A is -CH2CH2N(CH3)-, -CH2CH2NH-, -CH2NH-, or -CH2CH(CH3)NH-; and each RB is independently OR6, N(R6)2, NR6C(O)R6, halo, R6, C(O)R6, or NO2.
10. The compound according to claim 1, wherein said compound is of formula IV:

or a phannaceutically acceptable salt thereof.
11. The compound according to claim 10, wherein Ring E is phenyl or a 5-6 membered
heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur,
or a 3-7 membered monocyclic hcterocyclyl ring having 1-4 heteroatoms independently selected
from nitrogen, oxygen, or sulfur.
12. The compound according to claim 11, wherein:
Q is -CH2CH2O-, -CH2O-, -OCH2-, -OCH2CH2-, -CH(CH3)O-, -NHCH2-, -C(CH3)2O-, or -CH2S-.
-245-
AMENDED PAGE

WO2005/042497 PCT/US2004/036297
13. A composition comprising a compound of formula I and a phannaceutically acceptable carrier, adjuvant, or vehicle.
AMENDED PAGE
246
The present invention relates to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the R1, Z, Y, RA, and W groups of formula I are as defined herein. The invention also provides pharmaceutically acceptable compositions and methods of suing the compositions in the treatment of various disorders.

Documents:

01331-kolnp-2006- correspondence-1.2.pdf

01331-kolnp-2006-abstract.pdf

01331-kolnp-2006-assignment.pdf

01331-kolnp-2006-claims.pdf

01331-kolnp-2006-correspondence others.pdf

01331-kolnp-2006-correspondence-1.1.pdf

01331-kolnp-2006-description complete.pdf

01331-kolnp-2006-form 1.pdf

01331-kolnp-2006-form 13.pdf

01331-kolnp-2006-form 3.pdf

01331-kolnp-2006-form 5.pdf

01331-kolnp-2006-form-18.pdf

01331-kolnp-2006-form-26.pdf

01331-kolnp-2006-international publication.pdf

01331-kolnp-2006-international search authority report.pdf

01331-kolnp-2006-pct form.pdf

1331-KOLNP-2006-ABSTRACT 1.1.pdf

1331-KOLNP-2006-AMANDE PAGES OF SPECICATION.pdf

1331-KOLNP-2006-ASSIGNMENT 1.1.pdf

1331-KOLNP-2006-CLAIMS.pdf

1331-kolnp-2006-correspondence.pdf

1331-KOLNP-2006-DESCRIPTION (COMPLETE) 1.1.pdf

1331-KOLNP-2006-EXAMINATION REPORT REPLY RECIEVED.pdf

1331-kolnp-2006-examination report.pdf

1331-KOLNP-2006-FORM 1 1.1.pdf

1331-kolnp-2006-form 13-1.1.pdf

1331-KOLNP-2006-FORM 13.pdf

1331-kolnp-2006-form 18.pdf

1331-KOLNP-2006-FORM 2.pdf

1331-KOLNP-2006-FORM 3 1.1.pdf

1331-kolnp-2006-form 3-1.1.pdf

1331-kolnp-2006-form 5.pdf

1331-kolnp-2006-gpa.pdf

1331-kolnp-2006-granted-abstract.pdf

1331-kolnp-2006-granted-claims.pdf

1331-kolnp-2006-granted-description (complete).pdf

1331-kolnp-2006-granted-form 1.pdf

1331-kolnp-2006-granted-form 2.pdf

1331-kolnp-2006-granted-specification.pdf

1331-kolnp-2006-others-1.1.pdf

1331-KOLNP-2006-OTHERS.pdf

1331-KOLNP-2006-PETITION UNDER RULE 137-1.1.pdf

1331-KOLNP-2006-PETITION UNDER RULE 137.pdf

1331-kolnp-2006-reply to examination report.pdf


« Previous Patent
Next Patent »
Patent Number 258332
Indian Patent Application Number 1331/KOLNP/2006
PG Journal Number 01/2014
Publication Date 03-Jan-2014
Grant Date 31-Dec-2013
Date of Filing 18-May-2006
Name of Patentee VERTEX PHARMACEUTICALS, INCORPORATED
Applicant Address 130, WAVERLY STREET, CAMBRIDGE, MA 02139-4242
Inventors:
# Inventor's Name Inventor's Address
1 WILSON, DEAN, M. 9317, PIPILO STREET, SAN DIEGO, CALIFORNIA 92129
2 GONZALEZ, JESUS, E. III 12442, CARMEL CAPE, SAN DIEGO, CA 92130
3 ZIMMERMANN, NICOLE 11568, COMPASS POINT DRIVE NORTH, APT.54 SAN DIEGO, CA 92126
4 ZHANG, YULIAN 7689, PALMILLA DRIVE, SAN DIEGO, CA 92122
5 FANNING, LEV, T.D. 5157, LUIGI TERRACE #25 SAN DIEGO, CA 92122
6 TERMIN, ANDREAS P. 2080, WANDERING ROAD, ENCINITAS, CALIFORNIA 92024
PCT International Classification Number A61K 31/33
PCT International Application Number PCT/US2004/036297
PCT International Filing date 2004-10-28
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 60/515,088 2003-10-28 U.S.A.